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The increasing availability of sequencing data from genome-wide association studies and 
whole genome sequencing of the human genome has enabled rapid identification of genetic 
variations—mainly single nucleotide polymorphisms (SNPs)— in non-coding DNA of the 
human genome. However, it has been difficult to find the biological functions of the numerous 
SNPs in the genome. This gap in knowledge can be explained in part by our poor understanding 
of the function of non-coding DNA, and by the challenge of experimentally assigning function to 
SNPs that map to these non-coding regions. To clearly define the function of non-coding SNPs, 
we created genetically humanized mice to model human genetic variation in non-coding DNA in 
vivo. To generate the mice, we used a bacterial artificial chromosome (BAC) system harboring 
two genetically different human IL10 SNP haplotypes. The IL10 SNP haplotypes are “ATA” and 
“GCC,” which have been associated with differential IL-10 levels and disease susceptibility in 
humans. We found a robust allele-specific human IL-10 expression in both macrophages and 
CD4+ T cells. Specifically, GCC-hIL10BAC encodes for a high human IL-10 level relative to 
ATA-hIL10BAC in CD4+ T cells both in vitro and in vivo. The reverse was observed in 
macrophages. Accordingly, by complementing Il10 null mice with the GCC-hIL10BAC, namely 
Il10-/-/GCC-hIL10BAC mice, we were able to completely reverse disease outcome. The Il10-/-
/GCC-hIL10BAC mice were susceptible to persistent leishmania infection as evidenced by a 
high parasite burden in the liver and spleen. In contrast, like Il10 null mice, the Il10-/-/ATA-
hIL10BAC mice were refractory to disease.  Therefore, our data demonstrate that human IL10 
promoter SNP haplotypes alone can modulate IL-10 levels and disease risk. In the second part of 
this dissertation, we examined the regulation of IL-10 and its homolog, IL-24, as a means to 
indirectly demonstrate that we are not missing important regulatory elements within the 
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hIL10BAC. We chose IL-24 from the remaining cytokines within the Il10 gene cluster because 
the gene encoding for IL-24 is localized at the extreme end of the Il10 locus in both mouse and 
man and also human IL24 gene is not included in the hIL10BAC. Thus, finding co-regulation of 
IL-10 and IL-24 expression would suggest that the two homologs share common regulatory 
elements. Interestingly, we found that IL-10 and IL-24 are regulated by distinct cell-type-specific 
regulatory pathways. Optimal IL-24 expression requires Stat6 and Stat4 in macrophages and NK 
cells; meanwhile, IL-10 expression is independent of Stat6 and dependent on Stat4 only in IL-
12-treated NK cells. We also discovered an unexpected role for Type-I Interferons in mediating 
differential regulation of IL-10 and IL-24 expression in macrophages and NK cells. Thus, our 
results suggest that IL-24 and IL-10 are unlikely to share common regulatory elements within the 
Il10 locus. Altogether, our results undoubtedly demonstrate that we can model human genetic 
variation in non-coding DNA in vivo using genetically humanized hIL10BAC mice. In the 
future, the hIL10BAC approach can be extended to other human genes to accelerate rational 
development of safe and efficient personalized therapies, including vaccines.  
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1. Humanized mice  
1.1. Humanized mice: Rational and model systems 
 Laboratory mice have been instrumental in advancing our basic understanding of 
mammalian biological systems. Most current paradigms of human biology have been elucidated 
primarily in mice because inbred mouse strains are more amenable to genetic manipulation for 
studying the effects of specific genes in the absence of environmental factors. In fact, ~99% of 
mouse genes have detectable homologues in the human genome. Thus, many orthologous mouse 
and human genes such as receptors, growth factors, and transcription factors have similar 
functionalities. Similarly, global gene-expression profiles are conserved between mouse and 




strengthening the utility of mice as the 
model of choice to study human biology and disease.  
 Despite these similarities, there are many instances where mouse studies do not provide 
accurate model systems to study human biology, particularly in the field of gene regulation. For 
example, unlike coding regions which are well conserved between species, regulatory regions in 
non-coding DNA, which coordinate interspecies differences in gene expression between 
mammals
(2)
, are highly variable between mouse and human genomes
(3)
. In addition, ~80 million 
years of evolutionary distance separate mice and humans; thus, a number of species-specific 
differences between the mouse and human immune systems have been noted
(4)
. These inter-
species differences in gene expression are underscored by the observation that numerous 
pathogens—including HIV, hepatitis viruses, and the malaria pathogen Plasmodium 
falciparum—have a specific tropism for human tissues but not for mice. Thus, new drugs to treat 
these human-specific pathogens are most often hindered by lack of reliable, cost-effective, and 
predictive animal models that fully mirror human disease phenotypes. Accordingly, ~90% of 





 For several years, non-human primates (NHP) such as chimpanzees have been used as an 
alternative to small animal models in drugs and vaccines development because chimpanzees are 
the closest living animals to humans. Genetic variability between human and chimpanzee DNA 
sequence is ~5%
(6)
, suggesting that preclinical studies in chimpanzee are more likely to yield a 
more reliable surrogate for subsequent human trials. The use of chimpanzees in biomedical 
research, however, has been forbidden in many countries in Europe due to ethical issues, and in 
2011 the U.S. National Institutes of Health (NIH) stopped funding new research on chimpanzees 
in the United States. Therefore, chimpanzee studies are now limited to a handful of outbred 
animals which (as in humans) are hampered by inter-individual variability and hence are barely 
reproducible. 
 To address the limitations of using small animals as preclinical model systems, researchers 
have developed novel mouse models—referred to as “humanized mice”—that closely 
recapitulate human biological systems. A humanized mouse is a mouse in which functional 
human cells, tissues, or gene cassettes have been implanted. The most common models are mice 
with a functional human immune system (MHIS). MHIS are made by reconstituting 
immunodeficient mice with human peripheral blood cells (PBLs), human hematopoïc stem cells 
(HSCs), or lymphoid tissues that support the generation of a human immune system
(7-9)
. 
Examples are immunodeficient mice engrafted with human bone marrow, fetal liver and thymus 
fragments (BLT mice)
(10,11)
, or mice with a defective IL-2 receptor common gamma chain gene 
(Il2rγ
null
), which is required for T, B and NK cell development, reconstituted with the 
aforementioned human cells or tissues
(12-14)
.   
 Although MHIS have been very useful for studying human-specific pathogens and for 
testing human therapeutics, they have many limitations. The main limitation is that they do not 
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account for inter-individual variability in gene expression in humans. Current MHIS are 
generated on inbred mouse strains, which do not account for genetic differences in people. Thus, 
MHIS can be used for preclinical testing of drugs and vaccines, but cannot be used to investigate 
how different individuals respond differently to specific compounds and vaccines. This major 
drawback of MHIS can be overcome by having a mouse system in which one can model human 
genetic variation in non-coding DNA. To our knowledge that mouse does not exist yet; thus, the 
main goal of this dissertation is to generate a genetically humanized mouse model to investigate 
the impact of inter-individual variability on gene expression and disease susceptibility. 
 Other limitations of MHIS include the finding that species-specific factors such as HLA, 
cytokines, growth factors, and homing factors for tissues trafficking are structurally different 
between human and mice. For example, current MHIS cannot support development of human 
innate immune cells, including NK and myeloid cells
(15)
. Additionally, the effects of mouse 
innate immunity on engrafted xenogeneic human cells can diminish the efficiency of the 
engraftment
(7,9)
. The absence of mature lymph nodes, disorganization of lymphoid structure, and 
poor antibody responses due to impaired affinity maturation and class-switching have also been 
noted in MHIS
(7,9)
. These limitations can be overcome by injecting exogenous soluble 
factors
(16,17)
 or by hydrodynamic tail vein injection of DNA plasmid encoding human 
cytokines
(18,19)
. Additional technologies include transduction of human stem cells (HSCs) with 
mouse-specific factors such as mouse CD47, which is recognized by SIRPα expressed on 
phagocytic cells as a “do not eat me signal” to prevent engulfment of human cells by mouse 
macrophages
(20-23)
. Transgenic expression of human-specific factors
(21,24)
 and genetic alteration 






1.2. Transgenic humanized mice 
 Transgenic humanized mice have been made to solve some of the limitations of MHIS. 
Examples of  Transgenic humanized mice include mice carrying an exogenous gene cassette 
such as transgenic expression of cDNA constructs, Knock-in systems, and bacterial artificial 
chromosome (BAC) technology
(9,26)
. For the first approach, cDNA of a human gene is expressed 




This is achieved by directly 
injecting the cDNA construct into fertilized eggs of a female donor. The approach is often used 
for overexpression of a specific human gene to study function not regulation (because the cDNA 
construct lacks regulatory regions). The second approach is to replace the entire mouse gene 
(including exons and introns) with the human counterpart. Therefore, the human gene is 
expressed under the control of mouse regulatory DNA, which is not ideal for assessing human 
gene regulation. In contrast to the cDNA approach, Knock-in system relies on the use of 
embryonic stem cells (ES) as the basis to replace the mouse locus by the corresponding human 
gene by homologous recombination. Then, modified ES cells are implanted into the blastocysts 
to generate chimeras. Chimeric mice are later bred with appropriate mouse strains to obtain the 
desired genotype. Therefore, the knock-in approach is technically challenging and time-
consuming (at least 1-2 years)
(26)
. Moreover, ES cells are not available for all mouse strains, 
which limit the application of this strategy to only a few mouse strains. A third approach is to use 
large human genomic DNA cloned into a BAC vector. BACs are single-copy, F-plasmid cloning 
vectors that are often used to generate genomic libraries since they can support faithful 
segregation of giant inserts (100-300kb) into daughter cells
(26,28)
. Unlike knock-in mice, the 
expression of the human gene in the BAC is controlled by human regulatory DNA which is more 
appropriate for studying human gene regulation. Because the BAC insert is large enough, it is 
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Additionally, the mouse gene is not replaced; thus, both mouse and 
human genes are expressed, providing the opportunity to study species-specific differences in 
gene expression within the same mouse.  
 There are many benefits in using BACs over Knock-in technology, including speed and 
ease to make BAC transgenic mice. For example, when the appropriate BAC clone is identified, 
it takes only 3-6 months to get the founder mouse. There is no need for ES cells because the 
BAC insert is directly microinjected into fertilized eggs that are later implanted in the oviducts of 
pseudo-pregnant mothers. Furthermore, because of its size, the BAC transgene is insulated from 
chromatin interference, hence minimizing the positional effects on transgene expression
(29)
. 
Limitations of BAC transgenesis include difficulty assessing structural integrity of the construct 
once it is inserted into the mouse genome, copy-number effects on transgene expression, and 





 In the following sections, I will present current humanized mouse models to study human 










1.3. Humanized mouse models for modeling human gene regulation  
 Studying human gene regulation can be challenging not only because of the inter-
individual variability in gene expression among people but also because of the difficulty of 
getting tissue samples from healthy subjects. In fact, most human studies are limited to PBMCs 
that do not necessarily recapitulate tissue microenvironment of a living organism. 
 The mouse model of Down syndrome (also known as trisomy 21) is one of the first 
successful humanized mice for studying human gene regulation in vivo
(30)
. Down syndrome is a 
genetic disorder caused by the presence of an additional copy or part of human chromosome 21. 
This syndrome can be mimicked in mice by generating trans-species aneuploidy mouse strains 
harboring a copy of human chromosome 21 in addition to the entire set of mouse 
chromosomes
(31)
. Studies using this model have shown that more than 80% of human genes are 
expressed in mouse tissues
(31,32)
. The authors also confirmed that hepatocyte-specific gene 
expression and transcription factors binding patterns in this mouse mimic that of normal murine 
hepatocytes
(30)
. Because human chromosomes are studied exclusively in the context of murine 
transcriptional machinery and tissue microenvironment, the investigators clearly showed that 
DNA sequence rather than interspecies differences in epigenetics programs is responsible for 
driving species-specific gene expression
(30)
. Thus, this mouse was instrumental in demonstrating 
the utility of humanizing mice for studying not only human gene regulation but also human 
genetics. 
 BAC transgenic mice are currently the most popular model for examining human gene 
regulation in vivo because of the aforementioned advantages, but also because efficient 
homologous recombination technologies are now available to modify BAC construct in 
Escherichia coli
(33)
. These modifications include fusion of overlapping BACs, truncation of 
8 
 
putative regulatory elements within a BAC insert, and insertion of a reporter gene. An example 
of human BAC transgenic mice is the IFNG BAC mouse developed by Aune and colleagues to 
determine the role of distal regulatory regions within the human IFNG locus
(34)
. Using these 
mice, they confirmed that human IFN-γ is appropriately expressed in T lymphocytes and 
regulated by T-bet and Stat4, as one would expect. When they generated several transgenic 
strains with specific deletion of the BAC construct, they discovered a conserved non-coding 
region (CNS) located 30kb upstream of the transcription start site of the IFNG gene is necessary 
for human IFN-γ expression in T cells and NKT cells but not in NK cells. The CNS site was the 
target of transcription factor Runx3 and it is required for recruitment of RNA polymerase II to 
the IFNG locus. Thus, this study demonstrated the usefulness of BAC mice in studying human 
gene regulation.  
 About 10 years ago, our own group generated a human IL10 BAC transgenic mouse (also 
referred as hIL10BAC) to study human IL-10 regulation and function in vivo
(35)
. Because human 
IL-10 is biologically active in mice, we showed that we can faithfully study both regulation and 
function of the human gene in vivo. We demonstrated that regulation of human IL-10 expression 
is cell-type-specific. Specifically, human IL-10 was appropriately expressed in the myeloid 
compartment, which was sufficient to protect mice from sepsis
(35)
. Similarly, IL-10 was also 
expressed by regulatory T cells in the gut, which confers protection from colitis induced by gut 
microflora
(36)
.  Human IL-10, however, was weakly produced in splenic Th1 cells compared to 
mouse IL-10. Low human IL-10 in TH1 cells protected the mice from persistent leishmaniasis (as 
IL-10 plays a pathogenic role during leishmaniasis)
(35)
. Because the hIL10BAC carries a human 
IL-10 promoter haplotype associated with low IL-10 levels in humans
(37-39)
 and also resistance to 
cutaneous leishmaniasis, there was a possibility that human IL-10 expression in the hIL-10BAC 
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mouse is genetically controlled. Yet, at that time, we were not able to address this hypothesis due 
to the lack of a complementary mouse strain hosting a different human IL10 haplotype. 
Accordingly, in the next section, I will discuss the concept of humanizing mice for studying 
human genetics. 
 
1.4. Humanized mouse models for modeling human genetics 
 Studies looking at the association between genetic variants in the whole genome and 
human disease phenotypes are increasing dramatically. However, it is not clear whether these 
genetic variants—particularly those in non-coding DNA—have a functional/regulatory role. 
Therefore, there is a need for better tools to validate candidate variants in the context of human 
regulatory DNA to clearly link genotype to phenotype. Genetically humanized mice can be used 
for multiple purposes: (1) to model inter-individual variability in gene regulation patterns, (2) to 
identify subtle changes in transcription factor binding sites, (3) to assess allele-specific gene 
expression in specific cells or tissues, (4) investigate changes in mRNA splicing and stability, 
and (5) to test new therapies and vaccines at the preclinical stage.  
 In the literature, most of the successful genetically humanized mice produced to 
investigate human genetics were generated to model common monogenic disorders such as 




These mice are generally made by 
complementing a mouse strain that is null for a specific mouse gene with wild-type or mutant 
human genes. Because human and mouse genes have similar functionalities and tissue 
expression patterns, the disease phenotype (most often embryonic lethality) is monitored in mice 





, the human beta-globin transgenic mouse
(43)




 Emerging technologies that have the potential to advance the field of genetically 
humanized mice include zinc-finger nuclease (ZFN)
(45,46)
,transcription activator-like effector 
nuclease (TALEN)
(47-49)
, and Clustered Regularly Interspaced Short Palindromic Repeats 
CRISPR/Cas9 (CRISPR) technologies
(49-51)
. Briefly, these nucleases are used to create double-
stranded DNA breaks at specific locations of the genome, thus allowing introduction of the 
desired genetic modifications to target DNA sequence in the presence of a Donor DNA
(7)
. A key 
advantage of using these technologies is that DNA modification can be directly performed in 
fertilized oocytes, thus there is no need for ES cells (which are not available in all mouse 
backgrounds)
(7)
. Conversely, major limitations include low efficiency when dealing with large 
modifications, off-target edition of the genome, and mosaic gene expression due to the remaining 
nuclease activity
(7)
. A successful example of genetically modified mice using CRISPR was 




HTI is a fatal genetic disease caused by 
a deficit in Fumarylacetoacetate hydrolase (FAH), an enzyme which catalyzes the last step of the 
tyrosine degradation pathway in hepatocytes and renal tubal cells. The authors employed an 
existing mouse model of HTI that carries the same homozygous single base exchange G/A in the 





mutation creates a splice variant that gives rise to a truncated and unstable Fah protein. The 
Fah
mut/mut
 mice died from severe liver damage due to accumulation of toxic metabolites. By 
injecting a large volume of CRISPR components to correct the defective mutation, they were 
able to rescue the Fah
mut/mut
 mice from disease as measured by the loss of body weight
(52)
. 
Specifically, in mice in which the mouse Fah gene has been repaired, the hepatocytes can 
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expand and repopulate the liver similar to normal wild-type mice. Thus, this study demonstrated 
the feasibility of genome correction in vivo in adult animals to model a human genetic disorder. 
 
1.5. Utility of genetically humanized mice in post-GWAS era 
 The introduction of genome-wide association studies (GWAS) and whole genome 
sequencing has enabled rapid identification of genetic variants, mainly single nucleotide 
polymorphisms (SNPs) in non-coding DNA, that are enriched in diseased subjects compared to 
traditional candidate gene analysis
(54)
. However, it has been challenging to determine the 
biological function of the myriad of non-coding SNPs in the human genome. This gap in 
knowledge can be explained in part by the difficulty in defining the function of non-coding 
DNA, but also controlling for confounding variables in human studies. The confounding 
variables can be environmental factors, gene-gene interactions, or other SNPs in the human 
genome that are potentially in linkage disequilibrium with each other over several hundred 
kilobases across the genome
(55)
. GWAS variants also tend to have a small effect size, which 
means that they can explain only a small fraction of known disease heritability
(55)
. Furthermore, 
most human studies are limited to surrogate in vitro systems such as PBMCs or cell culture. 
Altogether, these limitations have led to a number of inconsistencies between studies. For this 
reason, the 2
nd
 chapter of my dissertation will focus on developing a genetically humanized 
mouse model that would be employed to clearly define effects of non-coding SNPs on gene 
expression and disease risk.  
 Since human IL-10 is the target gene in our BAC transgene, the following section will 





2. Genetic control of human Interleukin-10 expression 
2.1. Polymorphisms in the IL10 gene 
 IL-10 is a potent immune-regulatory cytokine that plays a key role in controlling 
excessive inflammation and autoimmune pathologies
(56)
. IL-10 exerts its anti-inflammatory 
function mostly through blockade of the production of pro-inflammatory cytokines by innate 
antigen-presenting cells
(57)
. IL-10 also inhibits the development of CD4+ Helper T cells, 
including TH1, TH2, and TH17, which are the cells that mediate host-protective immunity but also 
immuno-pathology
(57-59)
. IL-10 has been associated with various human diseases, including 
infectious and autoimmune diseases. These studies are based either on levels of IL-10 or on 
genetic polymorphisms in the IL10 gene. In fact, there is wide inter-individual variability in IL-
10 levels, leading to the hypothesis that differential IL-10-producing capacity among people may 
be genetically determined. Accordingly, heritability in IL-10 production—the proportion of 





 Several polymorphisms, including microsatellites and single-nucleotide polymorphisms 





(IL10-R and IL10-G) are two CA repeats at ~1.2kb and 4kb from the transcription start site
(62)
. 
The focus among the SNPs has been on three common polymorphisms at the proximal promoter 
of IL10, including -1082 G>A (rs1800896), -819 C>T (rs1800871), and -592 C>A 
(rs1800872)
(39)
. The alleles at position -819 and -592 are in complete linkage disequilibrium with 
each other, which means that they are inherited together. They make up three common 
haplotypes in human populations: GCC, ACC, and ATA. Frequencies of the haplotypes in 
Caucasians  are 51% (GCC), 28% (ACC), and 21% (ATA)
(39)
. However, haplotype frequencies 
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also vary depending on ethnicity. For example, the GCC haplotype is found in only ~5% in 





 So far, 21 SNPs have been identified within the IL10 locus (spanning ~4kb from the 
transcription start site to the last exon)
(64)
. Gibson and colleagues initially described three non-
coding SNPs among them as being distal IL10 haplotypes (65): rs1800890 (-3575 T>A), 
rs6703630 (-2849 G>A), and rs6693899 (-2763 C>A). Together, they form 8 distal haplotypes 
out of which 3 are common in Caucasian populations: TGC, AAA, and AGA at the frequency of 
51%, 26% and 13%, respectively
(65)
. Therefore, the 3 proximal SNPs may belong to a larger 
haplotype that may extend several kilobases away from the transcription start site. A graphical 










Figure 1.1. A graphical summary of common genetic variations in non-coding DNA of the IL10 
gene discussed in this chapter. The variants are microsatellites (IL10-R and IL10-G) and single-
nucleotide polymorphisms (SNPs) in the promoter (distal and proximal SNPs), in intron 2 





2.2. IL10 promoter SNP haplotypes and IL-10 expression  
 Crawley et al. were the first to investigate functional consequences of IL10 promoter 
haplotypes on IL-10 expression using a luciferase reporter assay
(66)
. They transfected a 
monocytic cell line (U937) with a pGL3 vector carrying part of the promoter (from -1137 to +25 
upstream of the transcription initiation site) of homozygous individuals for the IL10 promoter 
haplotypes GCC, ACC, and ATA. The ATA construct had the weakest IL-10 transcriptional 
activity, ACC was medium level, and the GCC had the highest expression level. In agreement 
with this data, when they assayed IL-10 levels in whole blood stimulated with LPS, they found 
that IL-10 levels were low in individuals homozygous for ATA when compared to GCC carriers. 
 Another group recently carried out similar studies to understand the molecular basis of 
human IL-10 transcription in macrophages
(38)
. They transfected a murine macrophage-like cell 
line (RAW264.7) with a luciferase reporter construct containing a region of IL10 promoter (-
1105 and +30). The constructs were engineered to harbor one of the -1082 SNP alleles (A or G, 
representing ATA and GCC haplotypes, respectively). When they stimulated the cells with LPS 
or apoptotic cells, -1082G had significantly more transcriptional activities than -1082A. Allele-
specific IL-10 expression in macrophages stimulated with apoptotic cells but not LPS was found 
to be regulated by poly(ADP-ribose) polymerase 1 (PARP-1), a transcriptional repressor that 
physically interacts with the IL10 promoter.  
 Along the same line, Steinke et al. also examined functionality of the  
-592C>A allele (formerly called -571) in Raji cells (a human B cell line that constitutively 




The presence of an A allele 
increases IL-10 promoter activity by 3.1-fold compared to a construct carrying a C allele at the 
same position. Remarkably, when they generated reporter constructs with specific deletions of 
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the IL10 promoter, the construct that includes -592C was found to have a reduced transcriptional 
activity (3.3-fold less) than any other constructs, suggesting the presence of a transcriptional 
repressor that is created by the C allele at this position. They also found that both alleles can bind 
to Sp1 and Sp3 transcription factors with similar affinity by means of EMSA and Supershift 
assays. Additionally, reconstitution of Sp1 expression in a Drosophila cell line lacking Sp family 
of proteins restored IL10 promoter competency in all constructs but not the one carrying the C 
allele. Thus, the findings indicate that a C to A mutation at position -592 increases IL-10 
production in human B cells, which is not in agreement with studies focused on human 
monocytes. 
 Despite these discrepancies between studies, the majority of the literature points to an 
increased expression of IL-10 in GCC (considered as a high IL-10 producer) over ATA carriers 
(low IL-10 producer). For instance, when Suárez and colleagues assayed PBMCs from 128 
healthy Caucasian donors, they found a higher constitutive mRNA expression in individuals 
homozygous for GCC compared to ATA carriers
(68)
. Similarly, healthy blood donors from 
Turkey and the United States were classified as high and low IL-10 producers based on an 
intronic IL10 SNP (rs1518111 G>A) known to be in tight linkage disequilibrium with IL10 
promoter haplotypes
(69)
. In the study, the donors carrying one or two G alleles of the intronic 
SNP expressed a more robust IL-10 level in PBMCs stimulated with LPS but also purified 







2.3. IL10 polymorphisms and disease susceptibility 
 Most of our current understanding regarding the role of IL-10 in diseases has been 
established in mice. In contrast, the majority of studies investigating the role of IL-10 in human 
diseases have been done by means of association studies. In fact, dysregulation of IL-10 
production has been associated with numerous human diseases, including infectious and 
autoimmune diseases. These associations are based on either levels of IL-10 or non-coding SNPs 
in the IL10 gene. Some examples of these studies will be presented in the following paragraphs. 
2.3.1. Infectious diseases 
 Human IL10 promoter SNPs have been linked to susceptibility to various chronic viral 
infections (HIV/AIDS and HBV), parasitic diseases (leishmaniasis and malaria), and bacterial 
infections (pneumonia and gastritis). In HIV-infected persons, individuals carrying the ATA 
haplotype (the low IL-10 producer) have an augmented risk of acquiring HIV and, once infected, 
progress more rapidly to AIDS
(64,70)
. These patients have lower levels of plasma IL-10, high viral 




In contrast, the ATA haplotype is more enriched in asymptomatic 
HBV carriers compared with subjects experiencing chronic liver disease
(73)
. In leishmaniasis, the 
presence of a C allele at position -819 is associated with an increased risk of developing 
cutaneous lesions
(74)
. Conversely, the A allele (-819A) augments the risk of gastritis in humans 
colonized with Helicobacter pylori. In addition, individuals carrying -1082A are less susceptible 
to develop cerebral malaria
(75)





These observations confirm the importance of IL-10 in regulating immune 





2.3.2. Autoimmune diseases 
 Polymorphisms in the IL10 gene have been implicated with many autoimmune diseases. 


















suggesting that having the ATA haplotype predisposes to inflammatory diseases. In addition, 
recent genome-wide studies (GWAS) have demonstrated strong association between 
polymorphisms in the IL10 gene with Bechet’s disease (BD)
(69,81)





The A allele of rs1518111 of IL10 has been associated with an impaired 




Similarly, the T allele of rs3024505, a 











Therefore, these studies strongly implicate genetic 














2.4. Genomic boundaries of the human IL10 locus 
 When the initial hIL10BAC mouse was generated, we found a weak human IL-10 
expression in CD4+ T cells. One possibility was that we may be missing regulatory elements 
required for normal human IL-10 expression in CD4+ T cells in the hIL10BAC. Since the exact 
genomic boundaries of the IL-10 locus in both mouse and human (Figure 1.2) —which also 
contains IL-19, IL-20, and IL-24 (all members of the IL-10 family of cytokines)—remains to be 
defined and also that our hIL10BAC does not contains IL20 and IL24, we took the approach of 
studying co-expression of IL-10 along with IL-24 which is located at the far end of the locus. 
The idea being if IL-10 and IL-24 are co-expressed or co-regulated, they may be sharing 
common regulatory elements within the locus that govern their cell-type-specific co-expression. 
For this reason, I will give some background information about IL-24 (in the next section) and 












hIL10BAC (~175kb) Not in hIL10BAC 
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3. Interleukin 24 
3.1. Cellular sources 
 IL-24 was first isolated by subtraction hybridation of cDNA libraries of human 
melanoma cells and originally named melanoma differentiation-associated gene 7 (MDA-7)
(84)
. 
Because of its genomic localization in chromosome 1 and sequence and structural homology 
with IL-10, it was later renamed as IL-24 and classified among the so-called IL-10 family of 
cytokines, including IL-10, IL-19 and IL-20
(85)
. IL-24 is expressed in various immune cells 
including T lymphocytes, monocytes, and B cells. Among these cells, IL-24 is robustly 
expressed in TH2 but not in TH1 cells after T cell receptor (TCR) activation with anti-CD3 and 




Thus, IL-24 is a prototypical Th2 cytokine and has been 




IL-24 expression can be induced in 




Meanwhile, B cell-specific IL-24 induction is achieved by cross-linking of the B cell receptor 




In addition to immune cells, IL-24 protein is secreted 
by non-hematopoïc cells including keratinocytes, melanocytes, and colonic sub-epithelial 




3.2. Biological functions and role of IL-24 in disease pathogenesis 
 IL-24 signals through two heterodimeric receptor complexes, namely  









To date, the 
exact function of IL-24 is not well defined because Il24 null mice have no unique phenotype
(98) 
;however, the current literature points to two main functions for IL-24 protein: (1) a classical 







 As a cytokine, ectopic expression of IL-24 induces secretion of IFN-γ, IL-6, and TNF-α 





IL-24 has been shown to mediate migration of neutrophils and monocytes in vitro as well 
as the recruitment of CD11b positive myeloid cells in vivo
(101)
.IL-24 also blocks the 
differentiation of germinal center B cells to plasma cells through down-regulation of 
transcription factors such as IRF4, Blimp1, and Bcl6 expression, which are critical for plasma 
cell differentiation
(102)
. Additionally, transgenic overexpression of IL-24 in the skin results in 
neonatal lethality, epidermal hyperplasia, and dysregulation of keratinocyte differentiation, 






 Most of the published literature about IL-24 focuses on its tumor suppressor activities on 





The mechanisms involved in IL-24-induced cancer cell death include activation 
of apoptotic pathways, regulation of the cell cycle, anti-angiogenesis effects, and increased 




Also, in a phase I clinical trial, 
Adenovirus delivery of IL-24 (Ad.MDA-7) induced the expansion of T cells, increased the 




 IL-24 has been implicated in the pathogenesis of autoimmune diseases such as psoriasis, 
inflammatory bowel disease, and rheumatoid arthritis. Up-regulation of IL-24 expression in 










colonic epithelial cells of patients with active ulcerative colitis and Crohn's 
disease
(109,110)







role played by IL-24 in these autoimmune conditions; however, remains to be elucidated. Recent 
studies also suggest a protective role for IL-24 during intracellular bacterial infection such as 
Mycobacterium tuberculosis
(112,113)
 and Salmonella typhimurium infections
(114)
 through induction 
of IFN-γ production by CD8+ T cells and neutrophils.  
3.3. Regulation in immune cells 
 Regulation of Il24 expression in immune cells is not well characterized. Sahoo et al. 




This region (-157 to +95 from the transcription start site) was trans-activated through cooperative 
binding of Stat6 (which acts downstream of the IL-4 receptor system) and c-Jun (an AP1 family 
of transcription factors) to turn on Il24 gene expression. Binding of Stat6 and c-Jun to this site 
was facilitated by an open chromatin structure defined by an increased binding of active histone 




The active chromatin architecture has also been 
confirmed to be Stat6-dependent because Stat6-deficient mice have a dramatically decreased 




In contrast to Th2 cells, 
Il24 promoter was occupied by histone deacetylase 1 (HDAC) in Th1 cells, which could explain 




Together, these studies suggest that Il24 gene is 
regulated at both transcriptional and epigenetic levels in TH2 cells; however, further studies are 
needed to clearly define the molecular mechanisms that govern regulation of IL-24 expression in 
other immune cell types.  
 In Chapter 3 of this dissertation, I will investigate the co-expression of mouse IL-24 and 
IL-10 expression to assess whether they share common regulatory pathways. This work would 
indirectly provide new insights regarding genomic boundaries of the IL-10 locus. Table 1.1 
shows key characteristics of IL-24 and IL-10 for purposes of this dissertation: 
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Chromosomal location 1q32 1q32 





Major cellular sources 




























Elucidating the impact of single nucleotide polymorphisms in 
non-coding DNA on cell-type-specific human IL-10 expression 














2.1.  ABSTRACT 
Genome-wide association studies (GWAS) have revealed that the majority of disease-
associated single nucleotides polymorphisms (SNPs) are found in non-coding DNA, yet little is 
known about the functionality of non-coding SNPs in the context of complex human diseases. To 
investigate the influence of non-coding SNPs on cell-type-specific gene expression and disease 
susceptibility, we created genetically humanized mouse strains based on a bacterial artificial 
chromosome (BAC) transgenic system. Each mouse was designed to harbor one of the two 
common human IL10 promoter SNP haplotypes: “ATA-hIL10BAC mouse” and “GCC-
hIL10BAC mouse.” By reconstituting Il10
-/-
 mice with either the ATA-hIL10BAC or the GCC-
hIL10BAC construct, we were able to examine the functionality of human IL10 promoter SNP 
haplotypes using IL-10-dependent mouse models of human diseases. In response to LPS 
stimulation, we found a differential human IL-10 production in myeloid compartment both in 
vitro and in vivo. The allele-specific human IL-10 expression in myeloid cells, however, was not 
sufficient to change the outcome of LPS-induced septic shock as evidenced by 100% survival 




/GCC-hIL10BAC. Conversely, in response to IL-
27, an IL-10-promoting cytokine, CD4+ T helper cells from GCC-hIL10BAC mice produce a 
significantly higher level of human IL-10 compared to ATA-hIL10BAC mice. In the Leishmania 
donovani, a mouse model of persistent infection, Il10
-/-
/GCC-hIL10BAC mice (like WT mice) 
had a high parasite burden in target organs in sharp contrast to Il10
-/-
/ATA-hIL10BAC mice that 
cleared the parasites. Furthermore, IL-10+IFN-γ+ CD4+ T cells—a cellular subset that has been 
associated with pathogen persistence during leishmaniasis—were significantly enriched in the 
spleen of Il10
-/-
/GCC-hIL10BAC but not in Il10
-/-
/ATA-hIL10BAC mice. Thus, we generated for 
the first time a robust experimental tool to functionally annotate human genetic variation in non-
coding DNA in vivo. Our results also strongly demonstrate that human IL10 promoter SNP 
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haplotypes alone can modulate cell-type-specific human IL-10 expression which subsequently 



















2.2.  INTRODUCTION 
When the first draft of the human DNA sequence was released about a decade ago, the 
rate of single nucleotide polymorphisms (SNPs) between two haploid human genomes was 
estimated to be 1 SNP for every ~1250 base pairs
(118,119)
. Additionally, 99% of sequence 
variation in the genome was mapped to non-coding regions, which also constitute the majority of 
the human genome
(118)
. This project was followed by the International HapMap and 1000 
Genomes project consortium, which together provided extensive databases of genetic variation in 
the human genome
(120,121)
. Despite these major accomplishments in the field of genomics, the 
functional significance of the millions of SNPs in the human genome is still not clearly defined. 
Numerous studies have linked non-coding SNPs to phenotypic variation and disease 
susceptibility among people by means of genome-wide association studies (GWAS)
(122,123)
. 
Similarly, non-coding SNPs have been associated with a change in gene expression in various 
human cells
(124-126)
. Nevertheless, it has been a daunting task to move from genetic association 
studies to causality for complex human diseases and traits. This is due in part to the lack of 
robust research tools for accomplishing the following: (1) to distinguish functional non-coding 
SNPs from other genetic variants that are in strong linkage disequilibrium with other large 
genomics regions across the genome, and (2) to define the function of important non-coding 
regions of the genome within which one or more important SNPs may be co-localized. 
Expression quantitative trait locus (eQTL) mapping is commonly used to identify 
genomic regions and variants that influence gene expression
(127,128)
. However, genotyping 
platforms used for eQTL analysis are designed to detect regions of linkage disequilibrium 
containing multiple SNPs rather than a single variant. Thus, eQTL mapping is not suitable to 
discriminate functional SNPs from innocent bystanders. In addition, computational predictions 
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and conservation-based methods have been employed to identify putative functional regulatory 
DNA but with limited success 
(129,130)
. For example, computational predictions are available to 
identify transcription-factor-binding-site motifs near or within GWAS-associated SNPs, yet the 
presence of a putative motif does not guarantee that a transcription factor will bind in vivo
(130)
. 
Furthermore, conservation-based approaches are used to define conserved non-coding sequences 
(CNS), which are highly conserved non-coding DNA that have been preserved between 
evolutionary distant vertebrate species, thus likely to harbor functional regulatory elements to 
drive cell-specific gene expression programs
(130,131)
. Still, one has to experimentally establish that 
the CNS of interest truly encode for functional cis-regulatory elements. This is usually done by 
cloning and testing their impact on gene expression using cell-based reporter assays or using a 
transgenic construct
(131)
. Additionally, conservation-based methods would likely fail to detect 
important species-specific regulatory elements 
(132,133)
.  
To provide a direct experimental approach for assessing the function of non-coding 
regions of the human genome, the  ENCODE project (Encyclopedia of DNA Elements) was 
initiated to annotate non-coding regions in various cell types
(134-136)
. The project used whole-
genome sequencing approaches to catalog regulatory features across the genome. The features 
mapped are coding and non-coding transcripts (by RNA-Seq), protein-coding regions (by mass 
spectrometry), transcription-factor-binding-sites (by ChIP-Seq), chromatin structure (by DNAse-
Seq, FAIRE-Seq, histone ChIP-Seq and MNase-Seq), DNA methylation sites (by Reduced 
Representation Bisulfite Sequencing assay)
(136)
. This effort has shed light on important findings 
about the structure and function of the human genome. Experimental data from ENCODE was 
also integrated to additional resources such as GWAS, eQTL information, computational 





. Some major findings related to the topic of this dissertation include: (a) many 
non-coding SNPs overlap with predicted functional regions, (b) disease-associated SNPs are 
enriched within ENCODE-annotated functional regions, and (c) disease phenotypes can be 
linked to a specific cell type or transcription factor
(128,129,134,136)
.  
Despite this large advance in our understanding of how the genome is organized into 
discrete cell-type-specific non-coding regulatory units, the ENCODE project has many 
limitations: (1) the use of transformed cell lines, (2) ENCODE-annotated regulatory variants are 
based on correlative studies and were not validated, and (3) information on how ENCODE-
annotated regions may be working in an in vivo context was not provided. Because the broader 
goal for both the Human Genome Sequencing and ENCODE projects is to decipher the content 
of the genome and how it is organized and regulated to better understand the molecular basis for 
disease susceptibility, new research tools will be needed to advance our ability to link genomic 
sequences (genotypes) with functional outcomes (phenotypes).  
Several years ago, as a proof of principle to provide a clear experimental link between 
non-coding SNPs, gene expression and disease susceptibility, we took the approach to physically 
isolate one locus away from other genetic and environmental factors (the human IL10 locus)
(137)
. 
This approach is based on a transgenic system generated by introducing a bacterial artificial 
chromosome (BAC) into a mouse
(137)
. The BAC used to generate the mice (hIL10BAC) contains 
not only IL10 but also its neighboring genes: MAPKAPK2 and IL19. Additionally, as human IL-
10 can signal through the mouse IL-10 receptor
(27)
, we previously validated that human IL-10 is 
functional and appropriately regulated in vivo using well-established IL-10-dependent mouse 
models of human diseases
(137,138)
. Specifically, we found that hIL10BAC mice rescue Il10
-/-
 mice 
from LPS-induced septic shock and colitis, which was associated with sufficient IL-10 
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. However, hIL10BAC 
failed to promote persistent Leishmania donovani infection in Il10
-/-
 mice because only a small 
fraction of splenic Th1 cells co-expressed human IL-10 (which is the pathogenic population in 
the context of leishmaniasis)
(139)
 induced after infection
(137)
. Because the hIL10BAC has an IL10 
promoter proximal SNP haplotype (ATA) associated with low IL-10 production in humans
(37-39)
, 
our data suggested that the impact of SNPs on human IL-10 expression may not be universal 
(i.e., same effects in all cells) as generally assumed, but rather differential between cell lineages 
or restricted to only certain cell types.  
 In this study, we sought to establish a proof-of concept experimental tool as a means to 
assign causality between genetic variants and human disease phenotypes in vivo and to determine 
the impact of genetic variation on non-coding DNA on cell-type-specific human IL-10 
expression and disease outcomes. Our working hypothesis is that non-coding SNPs in the IL10 
locus modulate IL-10 expression patterns in different cell types and thereby influence disease 
susceptibility. To this end, we developed a new humanized mouse harboring the alternate “GCC” 
haplotype block, which has been linked to high IL-10 levels in humans 
(37-39)
. We compared 
human IL-10 levels between the two mice in CD4+T cells and macrophages. Then, we 
confirmed the impact of cell- and allele-specific human IL-10 expression in vivo by employing 
the sepsis and Leishmania models. In LPS-stimulated macrophages, the GCC-hIL10BAC mice 
exhibit a lower IL-10 producing capacity when compared to ATA-hIL10BAC mice. However, 
the lower human IL-10 level in LPS-stimulated macrophages was sufficient to rescue Il10
-/-
 mice 
reconstituted with the GCC-hIL10BAC transgene from LPS-induced septic shock similar to Il10
-
/-
/ATA-hIL10BAC mice. On the other hand, human IL-10 was robustly produced in in vitro-
generated CD4+ T helper cells from GCC-hIL10BAC relative to ATA-hIL10BAC mice. Unlike 
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in macrophages, high IL-10-producing capacity in Th1 cells was sufficient to restore 
susceptibility of Il10
-/-
 mice from persistent leishmaniasis. Therefore, by assessing two divergent 
immune cell populations—CD4+ T cells and macrophages—we strongly demonstrate that we 
can model human genetic variation in non-coding DNA in vivo in mice. We also found that the 






















2.3. MATERIALS AND METHODS 
2.3.1. Generation of a GCC-hIL10BAC transgenic mouse  
2.3.1.1. Selection of BAC clones: 
 The University of California Santa Cruz (UCSC) Genome Browser 
(http://genome.ucsc.edu) was used to identify BAC libraries that have similar genomic 
organization and size as the RP11-262N9 (Existing ATA-hIL10BAC). DH10B E. coli strain 
carrying BAC clones were purchased from Invitrogen (Carlsbad, CA) and grown on LB agar 
plates under chloramphenicol selection (12.5 µg/ml) (Affymetrix, Santa Clara, CA). Three 
separate single bacterial colonies were selected from each plate and amplified with primers 
specific for two of the human IL10 proximal promoter SNPs:  -1082G>A (rs1800896) and -
592C>A (rs1800872). PCR products were sub-cloned into a TOPO-TA cloning vector 
(Invitrogen, Carlsbad, CA) followed by sequencing. Two BAC clones were found to bear a 
“GCC” Human IL10 haplotype (CTD-3174K1 and CTD2563L3), but only one was the closest 
in length (CTD-3174K1) to the RP11-262N9. To ensure that the new BAC would be the same 
length as the existing BAC, a second BAC clone was used (CTD-2563L3) as a donor BAC to 
extend the length of the acceptor BAC (CTD-3174K1), which was missing approximately 
12,6kb of genomic DNA. A screenshot of this step is shown in Appendix 2.1 and sequences as 












Table 2.1: List of primers used to genotype IL10 promoter 
 













2.3.1.2. Modification of the CTD3174K1 acceptor BAC clone by homologous 
recombination 
 We designed a strategy in collaboration with Gene Bridges, the recombineering company 
(Heidelberg, Germany), to modify the CTD-3174K1 BAC clone by means of homologous 
recombination. A replacement cassette carrying 50bp homology arms was generated by PCR and 
cloned into a vector hosting a kanamycin resistance gene (Kan
R
). Homologous recombination 
was induced between the donor BAC and replacement cassette to obtain recombinant clones 
hosting 31kb of the 3’ far end (near IL19) of the Donor BAC (CTD-2563L3). Recombinant 
derivatives (Donor/Kan
R
) were screened by PCR and confirmed by sequencing. A 15.6kb 
containing the “missing 12.6kb portion” and Kan
R
 gene of Donor/Kan
R
 was transferred to a 
shuttle vector (pAmp). Recombinant subclones (truncated Donor/Kan
R
) were identified by PCR 
and confirmed by sequencing. Correct recombinants were subjected to restriction digestion to 
release the DNA insert from the pAmp backbone. The insert (truncated Donor BAC/Kan
R
) was 
used as a modification cassette to extend the end of the Acceptor BAC (CTD-3174K1) by 
homologous recombination. The modified BAC clone (i.e., CTD-3174K1 BAC plus 12.6kb) 
were selected under chloramphenicol and kanamycin (Affymetrix, Santa Clara, CA) and 
screened by PCR followed by sequencing. The integrity of the construct was verified by PCR, 
restriction digestion, and sequencing. Glycerol stocks were made and stored at -80ºC for future 
use. A map of the Modified BAC made by Gene Bridges is shown in Appendix 2.2. 
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2.3.1.3 Preparation of BAC clones for Microinjection 
 DH10B E. coli hosting the Modified BAC clone were rescued on an LB agar plate and 
grown overnight in LB liquid media under chloramphenicol (15 µg/ml) and kanamycin (15 
µg/ml) selection. The BAC clone was purified by cesium chloride gradient purification and then 
digested with NotI digestion to obtain an insert of 175kb in length (as the ATA-hIL10BAC 
insert). The finalized construct was then microinjected into fertilized eggs of C57BL/6 
background at the NCI transgenic core facility. 
 
2.3.1.4 PCR Screening of founder mice 
 The VISTA Genome Browser (http://genome.lbl.gov/vista/index.shtml) was utilized to 
find regions of low homology between the mouse and human IL10 loci. PCR primers (5’-
CAGGCAAATCTGCATGGGATG-3’ and 5’-AGCTGTTGGACAGGCTCTACTG-3’) were 
generated to cover that region, which was an intergenic region between human IL10 and IL19. A 
tail sample was clipped from each founder mouse. DNA was isolated using a DNeasy Blood and 
tissue kit (Qiagen, Valencia, CA). Tail DNA specimens from wild-type and ATA-hIL10BAC 
transgenic mice were used as negative and positive controls, respectively. PCR results were also 
confirmed by Southern blot analysis.  
 
2.3.1.5 Estimation of transgene copy number 
Tail snips of at least 3 mice from 3 separate litters were obtained to assess the transgene 
copy number. Genomic DNA was isolated from tail tissues as described above and subjected to 
quantitative real-time PCR (qPCR) by targeting a region within exon 5 of the human IL19. qPCR 
primers were also designed to amplify a single copy mouse gene (coding portion of Jun 
35 
 
oncogene) and four homologous mouse genes of Bcl2a1 family (Bcl2a1a, Bcl2a1b, Bcl2a1c, and 
Bcl2a1d, which together represent 4 copies endogenous mouse gene). Estimates of the transgene 
copy numbers (RCN) were generated by normalizing the hIL10BAC to that of the mouse genes 
using the Delta CT method (2^- [target–standard]). The RCN was then multiplied by 2 for Jun 
and 4 for Bcl2a1 to infer transgene copy number. Primers and probes sequences are as follows: 
BAC-F: GAGTTGGCAATGCTGATTTT 
BAC-R: GGACAGGGTGTTCAAGGATCAT 
BAC-Probe: CAGGAGCCAAACCCCA  
(Jun) 001-Forward: GAGTGCTAGCGGAGTCTTAACC  
(Jun) 001-Reverse: CTCCAGACGGCAGTGCTT  
(Jun) 001-Probe: GAACTGGGGAGGAGGGCTCAGGGGC 
 (Bcl2a1) 004-Forward: GTTGCTTTCTCCGTTCAGAAGGA  
(Bcl2a1) 004-Reverse: GCCATCTTCAAACTCTTTTTCCATCA  
(Bcl2a1) 004-M2: ATTCCACGTGAAAGTC 
 
2.3.2. Mice 





/ATA-hIL10BAC, GCC-hIL10BAC, and Il10
-/-
/GCC-hIL10BAC. All mice were bred and 
maintained on C57BL/6J background under specific pathogen-free conditions at the Johns 
Hopkins University animal facilities. Gender- and age-matched mice were used for all 





2.3.3. Antibodies and Cytokines 
Purified hamster anti-mouse CD3ε (145-2C11) and purified hamster anti-mouse CD28 
(37.51) antibodies were purchased from BD Bioscience (San Diego, CA). Anti-mouse IL-4 
monoclonal antibody (11B.11) was obtained from the NCI Preclinical repository and anti-mouse 
IFN-γ antibody (XMG 1.2) was purchased from eBioscience (San Diego, CA). Recombinant 
murine IL-2 was obtained from the NCI repository as a donation. Recombinant IL-27 was 
purchased from R&D Systems (Minneapolis, MN). The following fluorochrome-labeled 
antibodies for flow cytometry were purchased from BD Bioscience (San Diego, CA): PercP-
conjugated anti-CD3, FITC-conjugated anti-CD4, PE-conjugated anti-mouse IL-10, PE-
conjugated anti-human IL-10, and APC-conjugated anti-IFN-γ. 
 
2.3.4 Preparation of media for primary cell culture 
Naïve T cells were cultured in RPMI 1640 medium (Lonza, Walkersville, MD) 
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) from Atlanta Biologicals, 
Inc. (Flowery Branch, GA), 2 mM of L-glutamine (Cellgro
®
, Mediatech, Inc., Manassas, VA), 
1X of non-essential amino acids (Gibco
®
, Life Technologies, Grand Island, NY), 1mM of 
sodium pyruvate (Gibco
®
, Life Technologies, Grand Island, NY), 10mM of 2-mercaptoethanol 
(Gibco
®
, Life Technologies, Grand Island, NY), 100 U/ml of penicillin (Cellgro
®
, Mediatech, 
Inc., Manassas, VA), and 100 mg/ml of streptomycin (Cellgro
R
, Mediatech, Inc., Manassas, VA). 
Bone marrow-derived macrophages (BMM) were cultured in  DMEM medium (Lonza, 
Walkersville, MD), supplemented with 10% of heat-inactivated FBS, 2 mM of L-glutamine, 10 
mM of 2-mercaptoethanol, 100 U/ml of penicillin, 100 mg/ml of streptomycin, and 50 µg/ml of 




2.3.5. Isolation and culture of naïve mouse CD4+ T cells 





 T cells from splenocytes by negative selection. All assay procedures 
were done according to the manufacturer’s protocols (R&D Systems, Minneapolis, MN). Three 
ml of cells at 10^6 cells/ml were seeded in a six-well plate that had been coated overnight with 
anti-CD3 and ant-CD28 antibodies. To block naïve CD4
+
T cells polarization toward TH1 or TH2, 
IL-4 and IFN-γ were neutralized with anti-IL-4 and anti-IFN-γ antibodies. Recombinant IL-2 (50 
UI/ml) was added as a survival signal. Recombinant mouse IL-27 (50 ng/ml) was added where 
indicated to induce IL-10 expression (140). On day 3, cells were harvested and spun down to 
collect supernatants. The cells were then washed, counted, and reseeded at 10^6 cells/ml into a 
fresh plate with no anti-CD3 or anti-CD28 antibodies but in media supplemented with anti-IL-4, 
anti-IFN-γ, IL-2, with or without IL-27. On day 4, cells were stimulated with 10 ng/ml of 
phorbol12-myristate 13-acetate (PMA) (Calbiochem, La Jolla, CA) and 1 µg/ml of Ionomycin 
(Calbiochem) for 8 hours and 24 hours. Supernatants were collected for human and mouse 
ELISA and cell lysates for mRNA analyses. Cells with no stimulation were used as negative 
control.  
2.3.6. Isolation and culture of bone marrow-derived macrophages 
Bone marrow cells were flushed from femurs and tibias of mice with the BMM culture 
media. The cells were then passed through a cell strainer, pelleted down and resuspended in the 
BMM media supplemented with 30% of L929-conditioned media from the American Type 
Culture collection (ATCC, Manassas, VA). The cells were seeded at 1x10
6
 per ml in 3 ml in a 6-
well plate and maintained for 5 days with media change at day 2 and day 4. At day 5, fully 
differentiated cells were washed three times with 1X PBS then maintained in BMM media 
38 
 
overnight. Fresh media was added at day 6 and the cells were stimulated with LPS (10 ng/ml) 
(Sigma, St. Louis, MO), IL-4 (10 ng/ml), and IFN-γ (10 ng/ml).  
 
2.3.7 mRNA Analyses 
 Total RNA was extracted with TRIzol® reagent (Ambion, Life Technologies, Carlsbad, 
CA). One microgram of RNA was used to make complementary DNA (cDNA) using the 
SuperScript® First-Strand Synthesis System (Invitrogen
TM
, Life Technologies, Carlsbad, CA). 
SYBRGreen assay real-time PCR (qPCR) assay from Applied Biosystems (Life Technologies, 
Grand Island, NY) was employed to amplify the cDNA. Mouse β-2-microglobulin was used as a 
housekeeping gene, thus all mRNA expression was normalized to that of β-2-microglobulin. The 
primers used for gene expression analysis were the following: 5’-
CAGGCAAATCTGCATGGGATG-3’ and 5’-AGCTGTTGGACAGGCTCTACTG-3’ for 
human IL10, 5’-TCGGCCAGAGCCACATG-3’ and 5’-
TTAAGGAGTCGGTTAGCAAGTATGTTG-3’  for mouse Il10, and 5’-
AAATGCTGAAGAACGGGAAAA-3’ and 5’-ATAGAAAGACCAGTCCTTGCTGAAG-3’ for 
mouse β-2-microglobulin. Data are shown as fold induction over non-stimulated cells (NS). 
 
2.3.8. Determination of human and mouse IL-10 production in vitro  
Cell-free supernatants were obtained by centrifugation at 1600 rpm for 5 minutes. Human 
and mouse IL-10 levels were quantified using the BD OptEIA human or mouse IL-10 ELISA 





2.3.9 In  vivo LPS challenge 
 Mice were challenged by intraperitoneal injection (i.p.) with 50 µg of LPS (List 
Biologicals, Campbell, CA) extracted from E. coli 0111:B4 strain. A set of mice (n=3) were 
sacrificed 2 hours after challenge to collect serum for human IL-10 quantification by ELISA. 
The remaining mice (n=5) were monitored for at least 2 weeks to determine survival rate after 
LPS-induced septic shock. 
 





/J) were used to maintain L donovani amastigotes 
(LV9) in vivo, as previously described (141). Each mouse was infected with 2x10^7 amastigotes 
by lateral tail vein injection. Parasite burdens in the liver and spleen were determined from 
methanol-fixed, tissue impression smears stained by the Giemsa method. Data are shown as 
Leishmania donovani Units (LDU). 
 
2.3.11 Assessment of Leishmania-specific CD4+ T cells by flow cytometry 
Mice were euthanized at the indicated time points (day 21 and day 28). Single cell 
suspensions were obtained and stimulated for 2 hours with PMA (20 ng/ml) and Ionomycin (1 
µg/ml). Brefeldin A (10 µg/ml) was added for 4 hours. The cells were collected then stained with 
anti-CD3 (PercP), anti-CD4 (FITC), anti-IFN-γ (APC), anti-mouse IL-10 (PE), and anti-human 
IL-10 (PE) (all from BD Bioscience). Samples were acquired (350,000 events total) on a BD 





2.3.12 Statistical analysis 
Data were analyzed using GraphPad Prism version 5.0. Software (La Jolla, CA). 
Unpaired Student’s t-tests were used for statistical analysis. A two-tailed p-value less than 0.05 
























2.4.1. Generation and initial characterization of GCC-hIL10BAC mice 
To generate a genetically humanized mouse with a “GCC” IL10 promoter SNP 
haplotype, we employed the University of California Santa Cruz (UCSC) genome browser that 
contains the list of available BAC clones. We identified a BAC clone (CTD-3174K1) in which 
human IL10 gene was centrally positioned and flanked by MAPKAPK2 and IL19 genes (as in the 
existing ATA-hIL10BAC). We used PCR analysis followed by sequencing to confirm that the 
BAC clone harbors the “GCC” IL10 promoter SNP haplotype. To directly compare the effects of 
SNPs on gene expression and disease phenotypes, it was important that both transgene constructs 
have the same length. Thus, we modified the CTD-3174K1 clone by means of homologous 
recombination with a donor BAC (CTD-2563L3) followed by restriction digestion to obtain a 
construct of 175kb in size as in RP11-262N9 (Figure 2.1A). Founder mice were screened by 
Southern blot and PCR analyses (Figure 2.1B and 2.1C). Fourteen founder mice (named A 
through O, excluding K) were positive for human IL10 by Southern blot analysis; however, only 
seven lines were expanded for future characterization. The remaining lines were discontinued for 
3 main reasons: (1) Southern blot and PCR data were discordant, (2) no transgene expression in 
vivo, (3) no litters from breeder pairs after several months. All the mice were in good health with 









Figure 2.1. Generation of GCC-hIL10BAC mice 
(A) Strategy to develop a GCC-hIL10BAC construct by homologous recombination (HR).  
(B) Southern blot analysis of founder mice. (C) Genotyping of founder mice by polymerase 
chain reaction (PCR). Arrows indicate an example of hIL10BAC positive mouse for the 





2.4.2. Human IL-10 expression in the GCC-hIL10BAC mice is copy-number independent 
Previously, we demonstrated that expression of human IL10 transgene in ATA-
hIL10BAC mice is not impacted by the number of transgene copies (i.e., copy number 
effects)
(137)
. To verify that human IL-10 is regulated similarly in ATA-hIL10BAC and GCC-
hIL10BAC mice, we performed copy number analysis of the GCC-hIL10BAC transgene by real-
time PCR (qPCR). As in the ATA-hIL10BAC mice, copy numbers in the seven GCC-hIL10BAC 
founder lines ranged from 1 to 9 copies (Figure 2.2A). To assess copy number effects on 
transgenic human IL-10 expression, we challenged GCC-hIL10BAC mice with LPS for 2h to 
measure human IL-10 production in vivo. As expected, human IL-10 was produced at similar 
levels in all transgenic lines (Figure 2.2B), suggesting that there are no copy number effects on 
human GCC-hIL10BAC transgene expression in vivo. To confirm this finding in a different 
tissue sample, we stimulated single cell suspension from spleenocytes in vitro with LPS for 24 
hours. No substantial differences in transgenic human expression or endogenous mouse IL-10 
levels among the transgenic lines were observed (Figure 2.2C). Thus, as in the ATA-hIL10BAC 













Figure 2. 2. Characterization of the GCC-hIL10BAC mice  
(A) Human IL-10 copy number estimation of GCC-hIL10BAC mice (red dots) and existing ATA 
hIL10BAC mice (blue dots). (B) Human IL-10 production in serum 2 hours after LPS challenge 
(one of two independent experiments). Number on the top of each bar graph represents copy 
number of the transgene. (C) and (D) are human and mouse IL-10 levels, respectively in 










2.4.3. Tissue-specific human and mouse IL-10 expression patterns in the GCC-hIL10BAC 
mice 
Since we verified that human IL-10 expression is independent of copy number, we 
concentrated our analysis on one of the founder lines of the GCC-hIL10BAC mice, namely line 
A which has 3 copies of the human transgene. To determine whether the GCC-hIL10BAC 
transgene expresses appropriate tissue-specific human IL-10 expression, we assessed basal levels 
of human and mouse IL-10 mRNAs in tissues known to express human IL-10. The ATA-
hIL10BAC mouse (Line a) was used as a comparator. Human IL-10 transcript was constitutively 
expressed in all tissues assayed, but with varying degrees of expression (Figure 2.3). We 
observed similar levels of human IL-10 transcripts between ATA-hIL10BAC and GCC-
hIL10BAC mice in all tissues assayed, excluding the brain. In contrast, mouse IL-10 transcripts 
were barely detectable in the tissues tested (Figure 2.3), as previously shown
(137)
. Together these 
data suggest that, similar to the ATA-hIL10BAC transgene, the GCC-hIL10BAC construct 






Figure 2. 3. Endogenous IL-10 expression in various tissues 
Human and mouse IL-10 mRNA expression was assessed for ATA-hIL10BAC and GCC-
hIL10BAC mice. The data was normalized to mouse β-2 microglobulin and expressed as Fold 











2.4.4. Human IL10 promoter SNP haplotypes influence human IL-10 expression in 
macrophages  
 We and others have demonstrated that stimulation of bone marrow-derived macrophages 
(BMM) with TLR4 agonist (such as LPS) induces significant IL-10 production in vitro
(136,137)
. 
Thus, we used this knowledge to determine whether human IL10 promoter SNP haplotypes 
modulate human IL10 expression in macrophages. We treated BMM isolated from ATA-
hIL10BAC and GCC-hIL10BAC mice with LPS alone or LPS in combination with IL-4 and 
IFN-γ. We used these cytokines because we have previously shown that LPS and IL-4 co-
treatment resulted in a synergistic increase of human IL-10 expression, while co-stimulation with 
IFN-γ inhibited LPS-dependent IL-10 production
(137)
. We found that human IL-10 levels were 
significantly higher in LPS treated-BMM of ATA-hIL10BAC mice compared to GCC-
hIL10BAC mice at both mRNA and protein levels (Figure 2.4A and 2.4B). Predictably, mouse 
IL-10 levels in the two transgenic lines were the same (Figure 2.4C and 2.4D). Differential 
human IL-10-producing capacities were also observed after co-stimulation with LPS and IL-4 or 
LPS and IFN-γ (Figure 2.4A and 2.4B). These data suggest that the “GCC” promoter SNPs 
haplotype produces relatively lower levels of human IL-10 in macrophages compared to the 










Figure 2. 4. Human and mouse IL-10 expression in macrophages 
Human (A) and mouse IL-10 (C) production by bone-marrow derived macrophages (BMM) in 
ATA-hIL10BAC (blue bar) and GCC-hIL10BAC (red bar) mice 6 hours after stimulation with 
the indicated stimuli. (B) and (C) show human and mouse IL-10 mRNA expression in BMM 3 
hours post -stimulation. *p<0.05 and ***p<0.0001 (student t-test) comparing ATA-hIL10BAC 
to GCC-hIL10BAC mice. NS is Not stimulated cells (when upper case is used) and non-








2.4.5. Allele-specific human IL-10 expression in myeloid cells does not alter susceptibility to 
LPS-induced septic shock 
To verify whether the allele-specific human IL-10 expression in macrophages that we 
observed in vitro can be recapitulate in vivo, we challenged the two hIL10BAC mice with LPS 
for 2 hours, as this treatment is known to induce IL-10 production in all myeloid cells, including 
macrophages. In response to LPS treatment, the ATA-hIL10BAC mice expressed significantly 
higher amounts of human IL-10 compared to GCC-hIL10BAC mice (Figure 2.5A). Conversely, 
mouse IL-10 levels were the same in both transgenic strains (Figure 2.5A). 
It has been established that myeloid-derived IL-10 controls susceptibility to LPS-induced 
septic shock, a well-established mouse model of human sepsis
(142)
. In this experimental system, 
Il10
-/-
 animals died due to excessive secretion of pro-inflammatory cytokines
(143)
. To determine 
whether the allele-specific human IL-10 expression in myeloid compartment influences 
susceptibility to sepsis, we generated mice which express only the human transgene by 
reconstituting Il10
-/-





/GCC-hIL10BAC mice. We challenged these mice with low-
dose LPS (50 μg). WT and Il10
-/-
 mice were used as controls. Then, we monitored survival rate 
of the mice at 12-hour intervals for 2-week periods. Il10
-/-
 mice died by 48 hours post-challenge 
(Figure 2.5B), while all WT mice were resistant to death (Figure 2.5B). We have previously 
shown that Il10
-/-
/ATA-hIL10BAC mice are resistant to disease (100% survival similar to WT 
mice). Remarkably, Il10
-/-
/GCC-hIL10BAC mice were also refractory to septic shock. Thus, 
similar to ATA-hIL10BAC and WT mice, the amount of human IL-10 expressed by the GCC-
hIL10BAC cassette was sufficient to protect mice from fatal outcome during sepsis. Our results 
suggest that allele-specific human IL10 expression in myeloid cells does not influence 







Figure 2.5. Allele-specific human IL-10 expression in myeloid compartment does not 
influence susceptibility to LPS-induced septic shock 
(A) Human and mouse IL-10 production in serum of ATA-hIL10BAC (blue bar) and GCC-
hIL10BAC (red bar) transgenic mice challenged with LPS for 2 hours. (B) Survival of WT, Il10-
/-, ATA-hIL10BAC, and GCC-hIL10BAC mice after i.p. injection with LPS (n=5 for each 
strain, one of two independent experiments). **p<0.001 (student t-test) comparing ATA-














2.4.6. Human IL10 promoter SNP haplotypes influence human IL-10 expression in CD4
+
 
helper T cells 
 We previously established that human IL-10 expression in CD4
+
 helper T cells in the 
ATA-hIL10BAC mouse is weak
(137)
. To determine whether this low IL-10-producing capacity in 
CD4
+
 helper T cells is genetically controlled, we compared human IL-10 levels in splenic CD4
+ 





 under neutral conditions (Th0) or in the presence of IL-27 (which is known 
to promote IL-10 production in these cells)
(140)
. At day 3 of culture, IL-27-dependent human IL-
10 was strongly produced by GCC-hIL10BAC mice relative to ATA-hIL10BAC mice (Figure 2. 
6A). In contrast, there was no difference between mouse IL-10 levels in the two transgenic 
strains (Figure 2.6B). In addition, when we stimulated the cells at day 4 of culture with PMA and 
Ionomycin (PI), we observed a robust allele-specific human IL-10 production (high in GCC and 
low in ATA) between the two transgenic mice at both protein (Figure 2.6C) and mRNA levels 
(Figure 2.6E). As expected, mouse IL-10 protein and transcript levels were the same between the 
mice (Figure 2.6D and Figure 2.6F). Thus, our results demonstrate that human IL10 promoter 
SNP haplotypes alone can control IL-10 expression in CD4
+ 





Figure 2.6. Human and mouse IL-10 expression in CD4+ T cells 




 T cells cultured in either 
neutral condition (Th0) or in presence of IL-27 (Th0+IL-27) for 3 days. (C) and (D) represent 




 Th0 cells cultured +/- IL-27 for 4 
days and stimulated with +/- PI (PMA and Ionomycin) for 8 hours and 24 hours. (E) and (F) 




 Th0 cells cultured and 
stimulated as mentioned above (one of two representative experiments). **p<0.001 (student t-
test) comparing ATA-hIL10BAC to GCC-hIL10BAC mice.  NS is Not stimulated cells (when 





2.4.7.  Allele-specific human IL-10 expression in CD4
+
 helper T cells confers susceptibility to 
leishmaniasis 
Infection with L donovani, a protozoan parasite responsible of visceral leishmaniasis, 
results in persistent infection in WT mice while Il10
-/-
 mice clear the parasites
(139)
. In this setting, 
Th1-derived IL-10 is thought to promote pathogen persistence
(139)
. Also, our group has shown 
that Il10
-/-
 mice reconstituted with the ATA-hIL10BAC transgene (Il10
-/-
/ATA-hIL10BAC mice) 
are refractory to persistent infection due to low human IL-10 expression by Th1 cells
(137)
. 
Because GCC-hIL10BAC mice harbor a transgene which encodes for high human IL-10 levels 
in CD4
+
 helper T cells, we questioned whether allele-specific human IL-10 expression in CD4
+
 







/GCC-hIL10BAC with L donovani, and we followed the 
course of disease at day-21 and day-28 post-infection. We confirmed that WT mice were 
susceptible to chronic infection and that Il10
-/- 
mice were refractory to disease (Figure 2.7A and 
2.7B). In both WT and Il10
-/-
/GCC-hIL10BAC mice, parasitemia in the liver reached its 
maximum at day-21 post-infection and began to drop afterward (Figure 2.7A). Similarly, parasite 
burden increased steadily in the spleen of these mice during the first month of infection (Figure 




/ATA-hIL10BAC mice were not susceptible to chronic 
infection, as predicted. These data clearly demonstrate that the GCC-hIL10BAC and ATA-
hIL10BAC mice have a differential susceptibility to L donovani infection.  






 T cells 
for being the pathogenic source of IL-10 that mediates persistent infection during 
leishmaniasis
(137,139)
. Accordingly, like Il10
-/-
, mice in which Il10 gene  has been altered only in 
CD4+T cells are also resistant to disease, demonstrating that CD4+ T cells are the major cellular 
source of pathogenic IL-10 during visceral leishmaniasis
(144)
. Thus, we performed ICS analysis 
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/GCC-hIL10BAC mice at day-21 and day-28 post-infection. We 






 T cells in WT mice as well as the 
opposite in Il10
-/-
 mice (Figure 2.7C). Consistent with previous studies, this cell population was 
barely detected in Il10
-/-







 T were found at significantly higher frequency in Il10
-/-
/GCC-hIL10BAC 










 T cells that are involved in host protective immunity were also enhanced in 
Il10
-/-
/ATA-hIL10BAC relative to Il10
-/-
/GCC-hIL10BAC, but only at day-21 post-infection 
(Figure 2.7E). Together, the results demonstrate that allele-specific human IL-10 expression in 












Figure 2.7. Allele-specific human IL-10 expression in CD4+ T cells mediate differential 
susceptibility to persistent infection 
(A) and (B) represent parasite burden  in liver and spleen, respectively, of WT, Il10-/-, ATA-
hIL10BAC, and Il10-/-, GCC-hIL10BAC mice (n=5 for each strain, one of two independent 
experiments). LDU indicates Leishmania donovani unit (LDU). (C-E) Intracellular cytokine 
staining of splenic CD4
+ 
T cells restimulated in vitro with PI (PMA and Ionomycin) at day-21 




 (C), IL-10 (D) and IFN-γ
+
 (E). *p<0.05, **p<0.001, 
and ***p<0.0001 (student t-test) comparing ATA-hIL10BAC mice to GCC-hIL10BAC mice. ns 














The increasing numbers of GWAS, which link genetic variation in DNA to specific 
human diseases, have revealed that the majority of disease-associated SNPs lie in non-coding 
regions of the genome
(122,123)
. However, the ability to experimentally distinguish functional non-
coding SNPs from other genetic noise has remained a challenge. In this study, we sought to 
develop a genetically humanized mouse model to establish the biological role of non-coding 
SNPs on gene expression and disease outcomes. We focused on  human IL10 gene, an essential 
gene that limits inflammatory responses
(145)
. We postulated that non-coding SNP haplotypes in 
the IL10 locus control cell-type-specific human IL-10 expression and thereby disease 
susceptibility. We found that human IL-10 was produced in an allele-specific manner in 
macrophages both in vitro and in vivo following LPS stimulation. However, Il10
-/-
 mice 
expressing either the ATA-hIL10BAC or GCC-hIL10BAC transgene were resistant to septic 
shock. Conversely, in the presence of IL-27, CD4+ T cells isolated from GCC-hIL10BAC mice 
produced significantly higher levels of human IL-10 compared to that of the ATA-hIL10BAC 
mice. Additionally, Il10
-/-
 mice carrying the GCC-hIL10BAC construct was susceptible to 
persistent leishmaniasis due to heightened human IL-10 levels in Th1 cells co-expressing IL-10 
and IFN-γ relative to Il10
-/-
 mice reconstituted with the ATA-hIL10BAC. 
To our knowledge, we have developed for the first time, an experimental system that can 
be used to directly interrogate whether genetic variation in non-coding DNA of an endogenous 
human locus are functional in vivo. Our approach is based on a BAC transgenic model that has 
been proven to be a reliable approach to model tissue-specific gene regulation in vivo in many 
settings
(146)
. Unlike human studies, our genetically humanized hIL10BAC mice allow us to 
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control for extraneous genetic and environmental effects. Also, the hIL10BAC allows us to 
access cells types and tissues relevant to disease pathogenesis.  
In line with our approach, Chakravati et al. recently published an essay in which they propose a 
theoretical set of genetic criteria, based on the Koch’s postulates in microbiology, to assign 
causality between genetic variation in non-coding DNA and complex human diseases
(147)
. In this 
essay, he proposed a set of 4 criteria to establish a causal link between non-coding SNPs and 
disease risk, as shown Box 1.  
 
 
Together, the criteria recommended combining data from genetic epidemiology in humans with 
experimental evidence from model systems such as genetically engineered mice to define the 
function of genetic variants in the human genome. In this dissertation, we focused on human 
IL10 gene as a proof of principle. In agreement with the first criteria, IL-10 is implicated in the 
pathogenesis of many human diseases, including leishmaniasis
(148-152)
. Also, disruption of the 
From: A. Chakravarti et al. 
Cell. September 26, 2013 
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Il10 gene in mice recapitulates phenotypes that are relevant in humans, thus fulfilling the second 
criteria
(139,142,143,153,154)
. Finally, by generating two genetically different hIL10BACs, we 
demonstrated that we can faithfully change disease outcome in Il10 null mice carrying one of the 
human IL10 alleles, thus providing a proof for criteria 3 and 4
(147,155)
.  
In addition to providing a new approach to functionally annotate non-coding SNPs in 
vivo, we also demonstrated that the impact of IL10 SNP haplotypes on gene expression is cell-
type-specific. Thus, our data validate some of the major findings of the ENCODE data as well as 
work from independent investigators using human cell-based studies. Specifically, the ENCODE 
project (like in our study) revealed that non-coding SNPs overlap with putative functional units, 
sometimes in a cell-type-specific manner, suggesting that these sequence variants may be 
causally linked to disease phenotypes
(128,134-136)
. Similarly, when Fairfax and collaborators 
sampled primary human monocytes and B cells from healthy donors, they discovered that 80% 
of non-coding SNPs that are linked to change in gene expression are specific to only one of the 
two cell types
(124)
. Similarly, in diseased donors, they found that GWAS-associated SNPs for 
systemic lupus erythematosus (SLE) were predominantly found in genes expressed by B cells, 
while variants implicated with IBD were enriched in genes expressed by monocytes, suggesting 
an important role for non-coding SNPs in modulating cell-type-specific gene activity during both 
health and disease. Furthermore, two concurrent papers recently studied the influence of genetic 
variation on gene expression in resting and activated immune cells. The results from these 
studies also suggest that the functional consequence of genetic variation in non-coding DNA 
may be only detected in a context/cell-type-specific manner
(125,126)
. 
Although our genetically humanized hIL10BAC mice provide a robust experimental tool 
to investigate human genetic variation in non-coding DNA, some limitations of this study should 
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be noted. First, we found high human IL-10 levels in macrophages from ATA-hIL10BAC 
compared to GCC-hIL10BAC mice. These findings are not in agreement with PBMCs-based or 
cell lines studies in which the “GCC” human IL10 haplotype was associated with high IL-10-
producing capacity
(38,39,69)
. Thus, more investigations are warrantied to determine whether the 
allele-specific human IL-10 expression that we observed in macrophages is dependent on the 
stimuli or receptor systems used to assess macrophage-specific human IL-10 expression in vitro. 
Secondly, we assayed human IL-10 production in CD4+T cells and macrophages only; thus, 
further studies are needed to assess allele-specific gene expression in other cellular sources of IL-
10. Thirdly, in the septic shock model, we used a low-dose LPS that was not lethal to WT mice 
(our control group). Thus, a sub-lethal dose of LPS could have revealed differences in survival 
rate between ATA-hIL10BAC and GCC-hIL10BAC mice. Finally, it is possible that the 
difference in survival and/or immune responses between the two genetically humanized mice is 
pathogen specific. This could have been addressed by investigating additional disease models 
such as Toxoplasma gondii and Influenza virus infections. Another possibility is the effect of the 
host (i.e., the genetic background of the mouse which is C57BL/6 in this study) on disease 
outcomes. We already have these mice backcrossed to BALB/c animals to test that likelihood in 
the future.  
In summary, we successfully developed a genetically humanized mouse model to study the 
influence of non-coding SNPs on human IL-10 expression and disease susceptibility. These mice 
would allow us to define in the near future the molecular basis of allele-specific human IL-10 
expression such as allele-specific DNA binding and chromatin architecture (in and around the 
SNPs) that coordinately regulate IL10 transcriptional activity. By combining immunological and 
molecular biology strategies to further characterize these mice, we believe we will gain new 
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insights on how genetics regulates human IL-10 expression. We also believe that our approach 
can be extended to other human genes to accelerate rational development of personalized 

















Appendix 2.1.  Bioinformatics search of the BAC clones used in this study 
This screenshot shows the search we performed using the University of California Santa Cruz 
(UCSC) Genome Browser (http://www.genome.ucsc.edu) to identify BAC clones which not only 
harbor human IL10 gene but also have the same size as our Existing BAC (RP11-262N9 colored 
in light green). Human chromosome 1 is represented at the top of the diagram. Chromosomal 
location of IL10 is marked with a red bar. The Left end panel shows the list of human BAC 
clones that overlap with IL10.   The BAC clones used in this study are as follows: Acceptor BAC 
(CTD-3174K1; pink; chromosomal location: chr1:206,816,360-207,021,737; length: 205,378 
bp), Existing BAC (RP11-262N9; light green, chromosomal location chr1:206,853,401-
207,034,489; length: 181,089 bp), and Donor BAC (CTD-2563L3; light blue, chromosomal 









































Cell-type-specific regulatory control of IL-10 
and IL-24 expression in murine macrophages 











3.1.  ABSTRACT 
 The IL-10 locus of cytokines include of Il10, Il19, Il20, and Il24 genes which together 
form a cytokine cluster spanning ~145kb on both mouse and human chromosome 1q32. Like the 
prototypical TH2 locus, clustering of these four cytokine genes is thought to coordinate their 
expression through shared genomic elements as well as their biological functions.  However, in 
the Il10 locus, only IL-10 and IL-24 are co-expressed in TH2 cells. The regulation of IL-24 in 
other cellular sources of IL-10 and its role in immune responses are not well defined. To 
determine whether Il10 and Il24 share common regulatory pathways, we examined IL-24 
expression in macrophages and NK cells, which are important cellular sources of IL-10. In LPS-
stimulated macrophages, optimal IL-24 expression requires IL-4 and Stat6 while IL-10 
expression is not mediated by Stat6. Similarly, in IL-2-stimulated NK cells, IL-10 expression is 
independent of IL-4, but IL-24 is robustly induced by IL-4/Stat6. We found five putative Stat-
binding elements, including one at the proximal promoter of the Il24 gene. Each site interacted 
with IL-4-induced Stat6 in macrophages and NK cells. Remarkably, Stat4 was also enriched to 
these sites in IL-12-stimulated NK cells, but not in macrophages. In NK cells, IL-24 induction 
required type I IFN receptor signaling regardless of the stimuli being added; meanwhile IL-10 
expression required type I IFNs only in macrophages. Post-translational histone modifications in 
the Il24 gene were mediated by IL4/Stat6 in macrophages but not in NK cells. Thus, we 
demonstrated that although IL-10 and IL-24 are co-expressed in macrophages and NK cells, they 






3.2.  INTRODUCTION 
Homologous genes in clusters can be coordinately regulated to synchronize gene 
expression programs and biological functions. In the eukaryotic genome, there are several 
important complex loci containing multiple genes such as the β–globin gene cluster and the Th2 
locus. Numerous reports have demonstrated that these genes are co-regulated through 
cooperative actions of distal regulatory elements with promoters and trans-acting factors in a 
cell-type-specific manner 
(156-158)
. On the other hand, some cytokine gene clusters have distinct 
gene regulatory programs despite being in relatively close proximity.  The human IFNG locus 
which includes IFNG, IL26, IL22 genes for instance, have unique gene expression patterns 
governed by discrete, gene-specific regulatory elements
(159)
. Therefore, these loci can serve as 
models to study the regulation of other gene clusters such as the murine Il10 locus which has not 
been well studied. 
The Il10 gene is localized in chromosome 1 (1q32) along with other members of the IL-
10 family of cytokines: IL-19, IL-20, and IL-24.  The latter was the first IL-10 homologous gene 
identified and historically named melanoma differentiation-associated gene 7 (mda-7)
(84)
. 
Although Il24 and Il10 genes are at the opposite end of the locus and transcribed in different 
directions, they are co-expressed in TH2 cells
(86-88,160)
. In contrast, Il19 and Il20 gene products are 
mostly produced by myeloid and epithelial cells but not by T lymphocytes
(161)
. These 
observations suggest that IL-10 and IL-24 expression may be synchronized in TH2 cells and 
other IL-10-producing cell types through shared genomic elements like in the classical TH2 
cytokine locus, consisting of the Il4, Il5 and Il13 genes
(157)
 and the IL17A/IL17F locus
(162)
.  
Unlike IL-10, of which the expression patterns have been well described in many cell 
types
(160)
, we are just beginning to characterize the cellular sources of IL-24. In mice, IL-24 is 
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robustly expressed in TH2 cells and has been shown to be one of the strongest IL-4-induced Stat6 
target genes in these cells
(86-88)
. In addition to TH2 cells, TCR stimulation with anti-CD3 alone or 
in combination with IL-2 promotes IL-24 expression in murine T lymphocytes
(90,163)
. Similarly, 
cross-linking of B cell receptor with CD40 ligands and anti-IgM triggers IL-24 expression in B 
lymphocytes
(91)
. In human PBMCs, IL-24 is induced in polyclonally activated T lymphocytes 
and in monocytes/macrophages
(89,90)
. IL-24 expression has also been noted in non-immune cells 




In this study, we hypothesized that IL-10 and IL-24 are regulated by similar pathways 
such as shared signal transduction, transcription factors requirements, and epigenetic 
modifications. Thus, we characterized IL-10 and IL-24 expression pattern in macrophages and 
NK cells. We chose to study macrophages and NK cells because expression of IL-24 in these 
cells is not well defined, but also because macrophages and NK cells are classical innate immune 
cells and important cellular sources of IL-10
(160)
. In fact, the biological importance of 
macrophage-specific IL-10 on disease susceptibility has been well established in mice. For 
example, macrophage-derived IL-10 confers protection from LPS-induced septic shock
(164)
. In 
contrast, the role of NK-specific IL-10 is not completely understood. Though NK-derived IL-10 
has been implicated in protecting from immunopathology during infection with rapidly 
disseminating pathogens such as Toxoplasma gondii and Yersinia pestis
(165)
, as well as in chronic 
mouse cytomegolavirus (MCMV) infection
(166)
.  
Because Il10 and Il24 genes are localized at the extreme ends of the locus, we thought 
that studying IL-10 and IL-24 co-expression would also be helpful in defining the genomic 
boundaries of the Il10 locus. We found that IL-24 and IL-10 can be co-expressed in NK cells and 
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macrophages but only in the presence of IL-2 and LPS, respectively. We also found that the 
effects of IL-2 and LPS on IL-24 expression could be enhanced by addition of IL-12 (in NK 
cells) or IL-4 (in both NK cells and macrophages) in Stat4 and Stat6-dependent manners. IL-4-
induced Stat6 and IL-12-induced Stat4 were recruited to multiple intronic sites of the Il24 locus. 
Histone modifications were also dependent on Stat6 and Stat4 in macrophages and NK cells, 
respectively. Interestingly, type I IFNs regulate IL-24 expression in NK cells but not in 
macrophages. The opposite was observed for NK- and macrophage-specific IL-10. Most 
importantly, our results clearly demonstrate that IL-24 and IL-10 are not co-regulated, as 
opposed to the well-defined TH2 locus, which suggests that they do not share common regulatory 













3.3.  MATERIALS AND METHODS 
3.3.1.  Mice 
Wild-type (WT) and Stat6
-/-
 mice on the C57BL/6 background were maintained at the 
Johns Hopkins University animal facility. WT and Stat4
-/- 
mice on BALB/c background were 
purchased from the Jackson Laboratory and bred at the same facility. All mice were maintained 
under specific pathogen-free conditions and were used between 8 and 12 weeks of age. All 
experimental procedures were approved by the Johns Hopkins University Institutional Animal 
Care and Use Committee. 
 
3.3.2.  Cytokines and antibodies 
Recombinant human IL-2 was obtained from the NCI repository as a donation. 
Recombinant murine IL-4, IL-12, and IL-13 were purchased from PeproTech (Rocky Hill, NJ). 
Purified Lipopolysaccharide (LPS) in lyophilized powder from Escherichia coli 0111:B4 was 
purchased from Sigma (St. Louis, MO). Stat6 (Sc-981) and Stat4 (Sc-486) monoclonal 
antibodies were obtained from Santa-Cruz Biotechnology (Santa Cruz, CA) and Stat5 antibody 
from R&D Systems (Minneapolis, MN). Acetylated histone H3 (AcH3; 06-599B) and Histone 
H3 lysine 27 trimethylation (H3K27me3; 07-449) were obtained from Upstate Biotechnology 
(Millipore, Billerica, MA). 
 
3.3.3.  Media for cell culture 
NK cell tissue culture media was prepared with RPMI 1640 medium (Lonza, 
Walkersville, MD) supplemented with the following: 5% or 10% heat-inactivated Fetal Bovine 





, Mediatech, Inc., Manassas, VA), 1X of Non-essential amino acids (Gibco
®
, Life 
Technologies, Grand Island, NY), 1mM of Sodium pyruvate (Gibco
®
, Life Technologies), 
10mM of 2-mercaptoethanol (Gibco
®
, Life Technologies, Grand Island, NY), 100 U/ml of 
penicillin (Cellgro
®
, Mediatech, Inc., Manassas, VA), and 100 mg/ml of streptomycin (Cellgro
R
, 
Mediatech, Inc., Manassas, VA). The culture media for the bone marrow-derived macrophages 
(BMM media) were made as follows: DMEM medium (Lonza, Walkersville, MD), 10% of heat-
inactivated FBS, 2 mM of L-glutamine, 10mM of 2-mercaptoethanol, 100 U/ml of penicillin, 
100 mg/ml of streptomycin, and 50 µg/ml of gentamycin (Quality Biological, Gaithersburg, 
MD).   
 
3.3.4.  Isolation and culture of murine NK cells  
Freshly isolated spleens were mashed in 5% fetal bovine serum (FBS) RPMI 1640 and 
passed through a cell strainer (BD) to obtain single-cell suspensions as previously described
(167)
. 
The cell suspensions were pelleted down by centrifugation. The red blood cells (RBC) were 
lysed from the pellet with ACK lysis buffer (Quality Biological, Gaithersburg, MD). RBC-free 
cells were washed and resuspended in 5% FBS RPMI 1640. The suspensions were passed 
through a sterile, pre-wetted nylon wool column and incubated for 50 mn at 37°C. Cells that 
were not bound to the nylon wool were eluted out with the 5% FBS RPMI 1640, washed, 
counted and resuspended in 10% FBS RPMI media supplemented with high-dose IL-2 (10,000 
U/ml). IL-2-conditionned cells were cultured for 6 days at a density of 1x10
6
 per ml to obtain 
mature NK cells as evidenced by expression of NK1.1 in 70-95% of the cells in culture. At day-6 
of culture, adherent cells were harvested following treatment with 1 nM of EDTA treatment 
(Quality Biological, Gaithersburg, MD), washed two times and starved for 3 hours to remove 
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any trace of IL-2. The cells were seeded at 3x10
6 
per well in a 6-well plate at a concentration of 
1x10
6
 cells per ml and stimulated with the following cytokines: IL-2 (100 UI/µl), IL-12 (10 
ng/ml), and IL-4 (10 ng/ml).  
 
3.3.5.  Isolation and culture of bone marrow-derived macrophages  
Bone marrow cells were flushed from femurs and tibias of mice with the BMM culture 
media. The cells were then passed through a cell strainer, pelleted down and resuspended in the 
BMM media supplemented with 30% of L929-conditioned media from the American Type 
Culture collection (ATCC, Manassas, VA). Three ml of the cells at 1x10
6
 per ml were seeded in 
a 6-well plate and maintained for 5 days with media change at day-2 and day-4. At day-5, fully 
differentiated cells were washed three times with 1X PBS then maintained in BMM media 
overnight. Fresh media was added at day 6 and the cells were stimulated with LPS (100 ng/ml), 
IL-4 (10 ng/ml), and IL-13 (10 ng/ml).  
 
3.3.6.  Messenger RNA isolation and analyses 
Total RNA was isolated with TRIzol® reagent (Ambion, Life Technologies, Carlsbad, 
CA). One microgram of mRNA was used as a template to generate complementary DNA 
(cDNA) using a SuperScript® First-strand Synthesis System (Invitrogen
TM
, Life Technologies, 
Carlsbad, CA). Quantitative real-time PCR (qPCR) was performed by SYBRGreen assay 
(Applied Biosystems, Life Technologies, Grand Island, NY). Murine β-2-microglobulin was 
used as a housekeeping gene and all mRNA expression was normalized to its levels. The primers 
used for gene expression analysis were the following: 5’-ACTTCAGCAGGCTGTGGG-3’ and 
5’-GATGACATCACAAGCATCCG-3’ for mouse Il24, 5’-TCGGCCAGAGCCACATG-3’ and 
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5’-TTAAGGAGTCGGTTAGCAAGTATGTTG-3’for mouse Il10, and 5’-
AAATGCTGAAGAACGGGAAAA-3’ and 5’-ATAGAAAGACCAGTCCTTGCTGAAG-3’ for 
mouse β-2-microglobulin. Data are shown as fold induction over non-stimulated cells (NS). 
 
3.3.7.  Chromatin Immunoprecipitation assay (ChIP) 
ChIP assay was conducted using an EZ-Magna ChIP kit from Upstate Biotechnology 
(Millipore, Billerica, MA). The assay was performed according to the manufacturer’s protocol 
with minor modifications. NK cells and BMM were stimulated for 2 hours with the appropriate 
stimuli and fixed with 1% paraformaldehyde (Fisher Scientific, Fair Lawn, NJ) for 10 mn. 
Nuclear lysates were obtained from the fixed cells and the DNA was sonicated on ice to obtain 
small fragments. Sonicated DNA was diluted in assay diluent in the presence of Protein A beads 
and protease inhibitors (all provided in the kit) and immunoprecipated with specific antibodies 
for 4 hours. The crosslink between DNA and proteins was reversed by protease K digestion at 
62ºC for 2 hours followed by incubation at 95ºC for 10 mn. The DNA was then purified in a 
spin-column and used as a template for qPCR. The primers used for qPCR are the following:  
Site 0: 5’-GGTCATGCTTCCCTGGAGAA-3’ and 5’-ACCCCCCTGTCTAAGAGCAAA-3’ 
which was initially published by Wei and al. in 2010
(88)
  
Site 1: 5’-CAGTTAACCCTGCTACCTTG-3’ and 5’-CAGGCCAACTTAAGCAG-3  
Site 2: 5’-CTGCTTAAGTTGGCCTG-3’ and 5’-CATCAAGAGGTTCTAGACTC-3  
Site 3: 5’-CCCCTGTGTGGTGTAGCTTCA-3’ and 5’- AAAGCCCTGCCTCTCATCCT-3 
Site 4: 5’-CAGAGGCCATTCCACACA-3’ and 5’-GGGGTCAGGTATGTTAATG-3’  
Non-IP control DNA was also treated on the side and used as Input. The results are shown as 
Percent of the Input (% Input). 
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3.4.  RESULTS 
3.4.1.  IL-24 and IL-10 have unique expression profile in NK cells and macrophages  
Previous studies have identified receptor pathways which regulate IL-10 expression in 
NK cells and macrophages
(167,168)
. The control of IL-24 expression in those cells types, however, 
is not well established. Utilizing IL-2-cultured splenic NK cells and bone marrow-derived 
macrophages (BMM) as models, we sought to define common pathways leading to IL-24 and IL-
10 induction in NK cells and macrophages. We stimulated NK cells and bone marrow-derived 
macrophages with stimuli that are known to induce IL-10 expression in these cell types. In NK 
cells, expression of IL-24 mRNA was dependent on IL-2 stimulation (Figure 3.1A). The 
combination of IL-2 plus IL-12 was highly synergistic in inducing IL-24 and IL-10 mRNAs 
(Figure 3.1A). Unlike IL-10, IL-24 expression was also enhanced upon stimulation with IL-2 
plus IL-4 in NK cells (Figure 3.1A). In macrophages, cytokines alone did not enhance IL-24 and 
IL-10 expression. Stimulation with LPS alone modestly turned on IL-24 expression, yet was 
sufficient for optimal IL-10 expression (Figure 3.1B). Conversely, co-stimulation with LPS and 
IL-4 or LPS plus IL-13 was required for optimal IL-24 expression in macrophages (Figure 3.1B). 
These results indicate that IL-24 and IL-10 can be co-expressed in NK cells and macrophages, 
but are regulated independently by different pathways. 
We next compared the kinetics of IL-24 and IL-10 expression using stimuli that induce 
both genes in NK cells (IL-2+IL-12) and BMM (LPS+IL-4). The cells were harvested every hour 
for up to 6 hours, and at 12 hours and 24 hours post-stimulation. Transcript levels were analyzed 
for each time point and the mRNA was normalized to non-stimulated controls of the same time 
points. As shown in Figure 3.1C, IL-24 mRNA expression in NK cells was weakly induced at 3 
hours after stimulation but reached its maximal levels at 6 hours post-stimulation. In contrast, IL-
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10 mRNA peaked earlier (3h) in NK cells followed by a second burst at 6 hours. In 
macrophages, IL-24 and IL-10 expression peaked at 3 hours post-stimulation and was sustained 
at lower levels up to 6 hours, and then were back to baseline level by 12 hours of stimulation 
(Figure 3.1C). These data demonstrate that IL-24 expression is delayed in NK cells compared not 













Figure 3.1. IL-24 and IL-10 are co-expressed in NK cells and macrophages  
NK cells (A) and bone-marrow derived macrophages (BMM) (B) were stimulated with the 
indicated stimuli for 6 hours and 3 hours, respectively. IL-24 (black) and IL-10 (gray) mRNA 
expression was determined by quantitative real time PCR (qPCR) in both cell types. Data are 
represented as fold increase over non-stimulated cells. Results in (A) and (B) are mean ± sem of 
three representative experiments. (C) and (D) show one of two independent kinetics studies in 
which IL-24 and IL-10 mRNA levels were assessed in NK cells stimulated with IL-2 plus IL-12 









3.4.2. IL-24 and IL-10 mRNA have similar half-life in NK cells but not in macrophages 
Having established the synergistic effects of cytokines such as IL-4 on IL-2-dependent 
and LPS-dependent IL-24 expression in NK cells and macrophages, respectively, we questioned 
whether this synergy is mediated through mRNA stabilization, which is known to be important 
in regulating IL-24 expression in keratinocytes
(95)
. Thus, we determined the stability of IL-24 
and IL-10 mRNAs by treating the cells with the transcriptional inhibitor Actinomycin D (ActD), 
after 3 hours of stimulation. Stimulated cells with no ActD treatment were used as control. 
Transcripts levels were assessed at 2h and 4h post-ActD treatment and normalized to control 
cells. IL-24 and IL-10 mRNA half-life were relatively short (less than 2h) in NK cells (Figure 
3.2A). Remarkably, IL-24 and IL-10 mRNA levels were reduced by 80% after 2 hours of ActD 
treatment in NK cells (Figure 3.2A). The addition of IL-4 or IL-12 did not have a stabilizing 
effect on IL-2-induced IL-24 and IL-10 mRNAs expression. In macrophages however, IL-24 
mRNA was highly stable and remained at the same level as non-treated controls for up to 4 hours 
following ActD treatment independently of IL-4 co-stimulation (Figure 3.2C). In contrast to IL-
24, up to 70% of IL-10 transcription was abolished after 2h of transcriptional blockade with 
ActD relative to control cells (Figure 3.2D). Thus, in NK cells, IL-24 and IL-10 mRNAs have 
similar mRNA stability, whereas, IL-24 mRNA is more stable than IL-10 in BMM. These data 
indicate that cytokine-dependent enhancement of IL-24 mRNA expression is not mediated 





Figure  3.2. IL-24 and IL-10 mRNA stability in NK cells and macrophages  
NK cells (A and B) and BMM (C and D) were treated with the indicated stimuli for 3 hours. The 
cells were then treated with ActD for 2 hours (black) and 4 hours (gray) to block transcription 
and follow half-life of mRNAs already made. Transcript levels were measured and normalized to 
non-stimulated cells for each time point. Data are represented as a percent of control mRNA 
expression which are cells with no ActD treatment (control: 0h; white) that were therefore set at 
100% mRNA expression. The data is based on one of two independent experiments. Dashed line 













3.4.3.  Stat6 is required for optimal IL-4-induced IL-24 expression in NK cells and 
macrophages 
Several groups have established that IL-4/Stat6 is a potent regulator of IL-24 and IL-10 
expression in TH2 cells
(86,88)
. Given the synergistic effects of IL-4 on IL-2-dependent IL-24 in 
NK cells and LPS-induced IL-24 expression in macrophages, we investigated the molecular 
basis of IL-4-induced IL-24 expression in NK cells and macrophages. Because IL-4 signals 
through Stat6 downstream of IL-4R, we examined IL-24 and IL-10 expression in WT and Stat6
-/-
 
mice. In NK cells, the synergistic effect of IL-2 plus IL-4 co-stimulation on IL-24 induction was 
greatly reduced in the absence of Stat6 (Figure 3.3A). Interestingly, IL-24 expression is not 
completely dependent on Stat6 in NK cells as IL-24 induction by IL-2+IL-12 remained intact in 
Stat6
-/-
cells. In macrophages, the effects of LPS plus IL4/IL-13 were also substantially 
diminished in Stat6
-/-
 relative to WT controls (Figure 3.3C). In contrast, Stat6 was largely 
dispensable for IL-10 expression in both cell types (Figures 3.3B and 3.3D). The data 
demonstrate that Sta6 plays an important role in regulating IL-24 expression in both NK cells 













Figure 3.3. IL-4-induced Stat6 mediates IL-24 expression in NK cells and macrophages  
Cultured NK cells (A and B) and BMM (C and D) were generated from WT (black) and Stat6 
deficient cells (gray). Cells were stimulated for 6h for NK cells and 3h for macrophages as 
previously described. IL-24 (A and C) and IL-10 (B and D) mRNA levels were measured by 
qPCR in each cell type and normalized to non-stimulated cells. Results show mean ± sem of tree 










3.4.4. Stat4 is required for maximal IL-24 and IL-10 co-expression in NK cells  
We have previously demonstrated that IL-12-induced Stat4 is required for optimal 
induction of IL-10 expression in NK cells
(167)
. Because IL-2 and IL-12 co-stimulation strongly 
induced IL-24 and IL-10 expression in NK cells, we hypothesized that Stat4 may be involved in 
NK-specific IL-24 expression. We measured IL-24 and IL-10 expression in Stat4
-/-
 and WT 
mice. As with IL-10, IL-24 expression was substantially reduced in Stat4-deficient NK cells 
(Figure 3.4A). Unexpectedly, in sharp contrast to IL-10, IL-24 mRNA expression was also 
diminished even in the absence of IL-12 stimulation (Figure 3.4A and 3.4B). The effect of Stat4-
deficiency on IL-10 expression was only evident under IL-12 stimulation conditions (Figure 
3.4B). In Stat4
-/-
 macrophages, there was a slight reduction of IL-24 mRNA expression in cells 
treated with LPS and IL-4, meanwhile IL-10 expression was unaffected by Stat4-deficient in 
macrophages (Figure 3.4C and 3.4D). These data suggest that Stat4 may be necessary for NK-
















Figure 3.4. Stat4 is essential for optimal induction of IL-24 and IL-10 in NK cells  
WT (black) and Stat4 deficient mice (gray) were used to generate and NK cells (A and B) and 
BMM (C and D). The cells were stimulated as previously described. IL-24 (A and C) and IL-10 
(B and D) mRNA levels were assayed by qPCR and normalized to cells with no stimulation. 
Results are mean ± sem of three representative experiments. The data are represented as fold 








3.4.5.  IL-24 and IL-10 expression is differentially regulated by Type-I Interferons  
To identify stimuli or receptor systems involved in Stat4-dependent, IL-12-independent 
IL-24 expression, we turned to type I interferon (IFN) signaling because IFN are known to 
activate multiple pathways, including Stat4
(169)
.  Additionally, recombinant INF-β has been 
shown to induce IL-24 expression in melanoma cells
(84)
 and IL-10 in macrophages
(168)
. We 
hypothesized that NK cells and macrophages express IFN in response to cytokine and LPS 
stimulation, which acts in an autocrine loop to enhance IL-24 expression in a Stat4-dependent 
manner. Therefore, we examined mRNA levels in cells lacking IFN-receptor-α (Ifnra
-/-
). WT 
cells were used as controls. In Ifnra
-/-
 NK cells, IL-24 expression was drastically reduced under 
all stimulation conditions in contrast to IL-10 which was not affected by the loss of IFN 
signaling (Figure 3.5A and 3.5B). We also examined the capacity of IFNs in directly inducing 
IL-24 and IL-10 mRNAs and found that IFN-β alone did not induce IL-24 expression in NK 
cells but synergize with IL-2 (Appendix 3.1A). In Ifnra
-/-
 macrophages, IL-24 expression was not 
affected, whereas IL-10 mRNA was reduced by half (Figure 3.5C and 3.5D). When we added 
recombinant IFN-β to WT macrophages, IL-10 mRNA was induced in contrast to IL-24 
(Appendix 3.1B). The data point to a differential regulation of IL-24 and IL-10 expression 












Figure 3.5. Cell-type-specific expression of IL-24 and IL-10 is mediated by Type-I IFNs  
Transcripts of IL-24 (A and C) and IL-10 (B and D) were determined in WT (black) and Ifnra-/- 
(gray) in NK cells (A and B) and macrophages (C and D). Results indicate mean ± sem of three 








3.4.6.  Cytokine-induced Stat4 and Stat6 are recruited to the Il24 locus in NK cells and 
macrophages  
We have previously shown that IL-12-induced Stat4 binds to an intronic site of Il10 in 
NK cells
(167) 
. We postulated that Stat4 and Stat6 may interact with the endogenous Il24 gene in 
NK cells and macrophages in a signal-specific manner. We first performed a bioinformatics 
search by scanning through the Il24 gene body looking for Stat-binding elements. Our search 
string identified five putative sites, including the previously identified Stat6 element at the 
proximal promoter of the locus
(86,88) 
. Genomic localization of the putative Stat-binding elements 
is shown in Figure 3.6. The four putative sites are located in intron 1, 2 and 5. The two sites that 
are next to each other in intron 1 are 23bp apart. We employed Chromatin Immunoprecipitation 
(ChIP) assay to examine Stat6 and Stat4 recruitment in NK cells and macrophages. In NK cells, 
IL-4-induced Stat6 and IL-12-induced Stat4 were enriched at the promoter and at the four 
intronic sites (Figures 3.7A and 3.7B), however, higher levels of Stat4 binding were found in 
comparison to Stat6 in NK cells (Figure 3.7B and 3.7A). Conversely, Stat6 and Stat4 binding 
was barely detectable in the absence of IL-4 or IL-12 stimulation. In LPS-stimulated 
macrophages, Stat6 but not Stat4 was recruited to the Stat-binding elements in response to IL-4 
stimulation. As expected, Stat6 binding was not observed in the absence of IL-4. The results 
demonstrate that Stat6 and Stat4 can physically interact with the endogenous Il24 gene in 











Figure 3.6. Map of the mouse Il10 locus displaying putative Stat-binding sites within Il24  
Panel A shows Il10 and its neighboring cytokines flanked by MAPKAP2 (3’ of IL10) and 
FAIM3 (5’ of IL10). Panel B displays genomic organization of the Il24 gene including the 6 
exons (blue boxes) and the 5’ and 3’ UTRs (gray boxes). Putative stat-binding elements are 














Figure 3.7. Stat6 and Stat4 are recruited to Il24 gene in NK cells and macrophages 
NK cells (A and B) and BMM (C and D) were stimulated for 2h with the indicated stimuli. 
Nuclear lysates were obtained to immunoprecipitate the DNA with antibodies specific for Stat6 
(A and C) and Stat4 (B and D). The DNA was then purified and amplified using primers 
targeting Stat-binding elements within Il24 gene. Data are presented as percent of Input DNA 










3.4.7.  Stat6 and Stat4 are involved in cytokine-induced histone modifications of Il24  
Previous reports found a link between Stat6 recruitment at the promoter and epigenetic 
changes such as histone modifications of IL-24 and IL-10 in TH2 cells
(86,88)
. We questioned 
whether the accessibility of the chromatin at the Il24 locus would change in the absence of Stat6 
and Stat4. We performed ChIP assays to look for enrichment of AcH3 (an active histone mark) 




 cells. In NK cells, the 
chromatin was poised in the absence of either Stat6 or Stat4, which was evidenced by enrichment 
of both AcH3 and H3K27me3 in Stat6- and Stat4-deficient cells (Figure 3.8A and 3.8B and 
Figure 3.9A and 3.9B). In macrophages, we observed lower levels of the active histone mark 
(AcH3) at the promoter and at the first intron in Stat6
-/- 
relative to WT macrophages (Figure 
3.10A). Conversely, higher levels of H3K27me3 were detected at the same site in Stat6
-/- 
compared to WT macrophages (Figure 3.10B). Unlike Stat6, Stat4 deficiency had no impact on 
the state of the chromatin in macrophages (Appendix 3,2). Thus, the effect of Stat6 on histone 
marks is mostly observed in macrophages, while Stat4 acts primarily in NK cells. The results 
suggest that cytokine-induced Stat proteins are involved in epigenetic tuning of the Il24 gene in 













Figure 3.8: Stat6-dependent histone modifications in NK cells 
AcH3 (A) and H3K27me3 (B) binding was measured by ChIP assay in WT and Stat6
-/-
 NK cells. 








Figure 3.9: Stat4-dependent histone modifications in NK cells 
NK cells were derived from WT and Stat4
-/-
 mice. AcH3 (A) and H3K27me3 (B) antibodies 
were used for ChIP assay. The DNA was then purified and amplified using primers targeting 
Stat-binding elements within Il24 gene. Data are presented as percent of Input DNA of one of the 






Figure 3.10: Stat6-dependent histone modifications in macrophages 
BMM were generated from WT and Stat6-/- mice. ChIP assay was performed using antibody 
specific for AcH3 (A) and H3K27me3 (B). The DNA was then purified and amplified using 
primers targeting Stat-binding elements within Il24 gene. Data are presented as percent of Input 






3.5.  DISCUSSION 
In this study, we considered the hypothesis that IL-10 and its homolog IL-24, share 
common regulatory features such as similar stimuli and transcription factor requirements that 
mediate their cell-type-specific expression. This hypothesis was based on the findings that IL-10 
and IL-24—but not IL-19 and IL-20 (also members of the Il10 gene cluster)—are co-expressed 
in murine TH2 cells
(161)
. Focusing on NK cells and macrophages, which are important innate 
cells, we demonstrated that IL-10 and IL-24 are co-expressed in a cell-type and stimuli-specific 
manner, yet not co-regulated. Although we found some similarities in IL-10 and IL-24 
expression patterns, such as their Stat4-dependency in NK cells and their co-expression in LPS-
treated macrophages, we predominantly uncovered more disparities outweighing their parallels. 
For example, we demonstrated that Stat6 mediates optimal expression of IL-24 in NK cells and 
macrophages, but is dispensable for IL-10 expression. Additionally, Stat6 binds to Il24 in a cell-
type and signal-specific fashion. We also found that IL-10 and IL-24 co-expression are under 
different regulatory constraints that are largely governed by Type-I IFNs. Together, our data 
suggest that—unlike the classical TH2 locus—IL-24 and IL-10 are regulated by distinct cell-
type-specific regulatory pathways, thus unlikely to share common regulatory elements. 
To determine which transcription factors are involved in cytokine-induced IL-24 and IL-
10 expression, we examined IL-24 and IL-10 mRNA induction in cells lacking Stat6 or Stat4, 
which are activated downstream of IL-4 and IL-12, respectively. We found that IL-4-induced 
Stat6 enhanced IL-24 but not IL-10 expression in IL-2-stimulated NK cells or in LPS-activated 
macrophages. Conversely, Stat4 regulates IL-24 expression in NK cells in the presence or 
absence of IL-12 stimulation, whereas IL-10 induction in NK cells is mainly controlled by IL-
12-induced Stat4. Thus, the effect of Stat6 is restricted to IL-24 in both NK cells and 
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macrophages, while Stat4 mediates NK-specific IL-10 and IL-24 co-expression. These findings 
are in contrast to the regulation of IL-10 and IL-24 expression in TH2 cells in which IL-24 and 
IL-10 co-expression is mediated by IL-4-induced Stat6 and TCR stimulation
(88)
. Conversely, IL-
10 is produced by Th1 cells under Stat4 and ERK pathways (but not IL-24)
(170)
 as opposed to 
Stat4-dependent IL-24 and IL-10 co-expression in NK cells. Hence, to our knowledge, our 
findings provide for the first time, molecular mechanisms, governed by cytokines and their 
cognate transcription factors (Stat6 and Stat4), in regulating IL-24 and IL-10 co-expression in 
innate cells. 
To understand the mechanisms underlying Stat4-dependent, IL-12-independent IL-24 
expression in NK cells, we considered other receptor systems that are known to induce Stat4 
phosphorylation. We decided to focus on type I IFN receptor signaling for three main reasons. In 
resting NK cells, there is a high level of phosphorylated Stat4 (p-Stat4) compared to other 
lymphocyte subsets, and such high basal p-Stat4 has been shown to be induced by IFNs
(169,171)
. 
In addition, it has been established that following LPS stimulation, macrophages produce type I 
IFNs, which then act via an autocrine loop to promote IL-10 transcription in macrophages
(168,172)
, 
hence, similar mechanisms could be in play for NK-derived IL-24 expression. Furthermore, IL-
24 cDNA was initially isolated by subtraction hybridation of human melanoma cells with 
recombinant IFN-β in the presence of mezerein
(84)
. Indeed, we found that while IFN-β did not 
directly induce IL-24 expression in NK cells, it did synergize with IL-2. Remarkably, IL-24 
induction in macrophages was completely independent of IFN signaling. To confirm these 
findings, we determined the expression of IL-24 and IL-10 in Ifnra-deficient cells and WT 
controls. In Ifnra
-/- 
mice, IL-24 transcript was substantially diminished in NK cells but not in 
macrophages. In contrast, IL-10 expression was intact in NK cells lacking IFN receptor 
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signaling, but was reduced by half in Ifnra
-/- 
macrophages. Therefore, our results suggest that IL-
24 and IL-10 expression are governed by an interferon-dependent gene-specific and cell-type-
specific regulatory pathways. 
We and others have shown that IL-12-induced Stat4 and IL-4-induced Stat6 bind to the 
Il10 gene in NK cells and Th2 cells, respectively
(86,88,167)
. To determine whether these Stats can 
directly interact with Il24 gene in NK cells and macrophages, we performed ChIP assays to 
assess Stat6 and Stat4 binding across the locus. We found that both Stats can bind to multiple 
sites across the Il24 locus, but in a signal- and cell-type-specific manner. Because Stat6 binding 
has been linked not only to acute transcription but also to epigenetic modifications of Il24 in TH2 
cells
(86-88)
, we questioned whether binding of Stat6 as well as Stat4 mediates post-translational 
modifications of the histones in the cell types assayed. As in Th2 cells, Stat6 was associated with 
recruitment of permissive histone marks (AcH3) at the Il24 locus in macrophages but not in NK 
cells. The opposite was observed when we assayed binding of H3K27me3 in Stat6-deficient 
macrophages. In contrast to Stat6, the lack of Stat4 did not influence the accessible chromatin 
structure in macrophages (as expected). In NK cells, the chromatin was poised (i.e., enriched for 
both active and silent marks) in the absence of Stat6 or Stat4. These data suggest that the effects 
of Stats on the epigenetic landscape of Il24 in NK cells are may be indirect through induction of 
other pathways. In addition to work done in TH2 cells and our own study, epigenetic studies on 
Il24 expression are scarce. Nevertheless, in Th1 cells where Il24 is barely expressed, the Il24 
promoter is occupied by histone deacetylase (HDAC) which has been associated with gene 
silencing 
(86)
. Similarly, in human melanoma cells, treatment with HDAC4 reduced binding of 





Although we identified signaling pathways and epigenetic events that govern IL-24 
expression in NK cells and macrophages, there are limitations to our study. We focused on 
changes in gene expression by assessing mRNA levels. We did not assay IL-24 protein because 
of the lack of commercial ELISA reagents. Thus, further studies are needed to confirm that 
protein and mRNA data match. In addition, Stat5-dependent Il24 expression was not investigated 
in NK cells because Stat5
-/-
 mice are not viable
(174)
 and also our in vitro culture system for NK 
cells is driven by IL-2/Stat5 signaling. We did investigate Stat5 binding in NK cells, but we did 
not observe any evidence for Stat5 enrichment to the Stat-binding sites assayed (Appendix 3.3). 
Nevertheless, Il24 expression in IL-2 stimulated T lymphocytes was reduced in mice genetically 
engineered to be deficient of Stat5 tetramers 
(163)
. In the same study, the authors revealed that 
Stat5 tetramers bind to a region within intron 1 of Il24 in T cells of WT mice by ChIP-seq. Also, 
another group recently identified a Stat5-binding element in a distal region upstream of Il24 in 
TH2 cells
(175)
 that was not investigated in this study. Because we found a role for type I IFNs in 
regulating IL-24 expression in NK cells and no Stat5 binding across the locus in NK cells, we 
now propose that IL-2 induces IL-24 expression in NK cells through production of IFNs, which 
in turn feedback to activate Stat4. Therefore, our findings point to cell-type-specific regulatory 
mechanisms that distinguish IL-2-dependent IL-24 expression in T cells from that of NK cells.  
In summary, this study provides insights into the molecular mechanisms that govern IL-
24 and IL-10 co-expression in NK cells and macrophages. We established that IL-10 and IL-24 
expression are regulated by different cell-type-specific pathways. So far, our working model of 
IL-24 and IL-10 regulation in NK cells and macrophages is as follows:  In NK cells, IL-2 alone 
or in combination with cytokines induce IFNs production. The IFNs act in an autocrine-fashion 
to activate Stat4, which is required for potent IL-24 expression in NK cells. Meanwhile, IL-12-
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induced Stat4 is sufficient for optimal IL-10 expression in NK cells. In LPS-activated 
macrophages, IL-4 activates Stat6 downstream of the IL4R. Stat6 binds to the promoter and 
other sites across the locus which facilitates opening of the chromatin and thereby enhancing 
expression of IL-24 transcription. In contrast to the regulation of IL-24, IFNs but not IL-4/Stat6 
is required for optimal macrophage-derived IL-10 expression. A diagram of this model is 


























Appendix 3.1: Type-I IFN-dependent expression of IL-10 and IL-24 in NK cells and 
macrophages 
NK cells (A) and macrophages (B) were stimulated with cytokines and/or LPS. IL-24 (black bar) 
and IL-10 (gray bar) mRNAs were assessed by qPCR and normalized to non-stimulated cells. 









Appendix 3.2: Stat4-dependent histone modifications in macrophages 
ChIP assay was used to assess enrichment of AcH3 (A) and H3K27me3 (B) in WT and Stat4
-/-
 










Appendix 3.3: Stat5 binding across the Il24 gene 
ChIP assay was conducted in NK cells to detect Stat5a binding to the putative stat-binding sites. 





























GENERAL DISCUSSION AND CONCLUSIONS 
Mouse models have been traditionally used to elucidate the underlying mechanisms of 
human diseases, as well as for testing candidate therapeutics, including vaccines at the 
preclinical stage. However, it has been difficult to translate knowledge gained from mouse 
studies in humans due in part to a number of differences between mice and human immune 
responses
(4)
. Thus, there is growing interest in developing faithful mouse models that fully mirror 
human biology, particularly inter-individual variability in gene expression and disease risk. 
One promising approach is the use of humanized mice containing human cells, tissues, 
organs, or genes. There are a number of successful humanized mice with varying utilities such as 
humanized mice with functional immune systems (MHIS), humanized mice for studying human 
gene regulation, and humanized mice for studying human genetics. In Chapter 1, we presented 
examples of these mice as well as their advantages and limitations. We also argued that existing 
humanized mice are not ideal for capturing the genetic diversity among people, especially 
sequence variation in non-coding DNA which constitutes most of the variability in the human 
genome
(118)
. Thus, in Chapter 2 we designed and generated for the first time a genetically 
humanized mouse to study the biological function of non-coding SNPs in the human IL10 locus.  
The hIL10BAC mice were made by introducing a bacterial artificial chromosome (BAC) 
carrying one of the two different human IL10 promoter SNP haplotypes into C57BL/6 mice: 
ATA-hIL10BAC and GCC-hIL10BAC mice. We choose human IL-10, a very important 
immuno-regulatory cytokine, as our target gene  for several reasons: (1) human IL-10 is known 
to cross-react with the mouse IL-10 receptor, enabling us to study both gene regulation and 
function in vivo;  (2) there is a strong genetic component to human IL-10 expression (reviewed in 
Chapter 1); (3) non-coding SNP haplotypes in IL10 promoter have been associated with 
101 
 
differential IL-10 levels and disease risk (Reviewed in Chapter 1); (4) Targeted deletion of IL-10 
in specific cells in mice demonstrated that cellular sources of IL-10 determine disease 
outcomes
(139,142,144,176)
. Thus, by testing these mice using well-established IL-10-dependent 
mouse models of human diseases (i.e., sepsis and leishmaniasis), we firmly established that IL10 
promoter SNP haplotypes control cell-type-specific human IL-10 expression and disease 
susceptibility.  
Together, the work presented in Chapter 2 contributes significantly to the body of 
knowledge regarding the utility of hIL10BAC humanized mice for modeling both human 
genetics and gene regulation in vivo. Key differences between the hIL10BAC humanized mice 
over existing humanized mice for investigating gene regulation is shown below. 
 
To date, the hIL10BAC humanized mouse can be used to elucidate the molecular basis of 
allele-specific human IL-10 expression. This could be achieved by assessing changes in 
transcription factor binding patterns in varying cell types in response to different stimuli. In fact, 





. Because those studies were conducted using bulk PBMCs or cell lines—which do 
not necessarily reproduce the epigenetic microenvironment of primary cells—it would be 
interesting to repeat these experiments in freshly isolated cells/tissues from ATA-hIL10BAC and 
GCC-hIL10BAC mice. Alternatively, one could perform a ChIP-Seq assay on CD4+ T cells +/- 
IL-27 to assess allele-specific Stat1 and Stat3 binding on hIL10BAC locus since IL-27-induced 
IL-10 production in CD4+ T cells has been shown to be dependent on both Stat1 and Stat3
(140)
. 
This could also reveal species-specific Stat1/Stat3 binding differences between human and 
mouse IL-10 genes in CD4+ T cells.   
In addition, a comparative sequence analysis between human and mouse IL-10 by our 
group has found 13 conserved non-coding sequences (CNS) within the hIL10BAC
(138)
. Some of 
these CNS sites appear to be important for tissue-specific IL-10 expression
(138)
. Because in vivo 
functional analysis of CNS has been done with success for certain genes such as IFNG
(179)
 and 
MYC (an oncogene involved in many human cancers)
(180)
, it would be interesting  to use similar 
approach in order to determine which CNS or CNS+SNPs are responsible for changes in gene 
expression and susceptibility to disease.  To do this, one could start by identifying SNPs that fall 
within these sites to refine the list of putative functional SNPs in hIL10BAC and then generate 
new mice with specific deletion of the CNS sites (CNS#hIL10BAC mice). Data obtained from 
CNS#hIL10BAC mice would be compared to existing ATA-hIL10BAC or GCC-hIL10BAC 
transgenes to define the function of the CNS and or CNS+SNPs removed from the hIL10BAC.  
Further studies could also investigate the impact of the allele-specific chromatin structure 
such as post-translational modifications of histone tails (i.e. acetylation and methylation) on gene 
expression. Finally, because existing  hIL10BAC mice allow us to study the global effects of 
“GCC” and “ATA” SNP haplotypes but not individual SNPs, it would be interesting to generate 
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a complementary mouse in which the G-C-C promoter SNPs are mutated back to A-T-A by site-
directed mutagenesis. This new mouse (ATA+GCC-hIL10BAC) would be critical to determine 
whether our findings (gene expression and disease phenotype) are caused by the promoter IL10 
SNPs only or by the cumulative effects of all the non-coding SNPs in the hIL10BAC. 
In the near term, the ultimate goal is to use the hIL10BAC humanized mice to test the 
activity of pharmacological compounds that have been designed to induce or inhibit IL-10 
production. In addition, our mice can be used to study the efficacy of recombinant human IL-10 
in treating various inflammatory diseases associated with dysregulation of IL-10 production.  
Furthermore, we can also test the effects of allele-specific IL-10 expression on the immune 
responses that are induced following immunization to vaccine candidates. By deciphering the 
molecular basis of allele-specific IL-10 expression, we might also be able to categorize people 
based on their IL-10 genotype to obtain a cohort of subjects ready to be enrolled in clinical trials. 
Finally, the hIL10BAC approach can be extended to other human genes for which a bacterial 
artificial chromosome and mouse-null allele are available. 
In Chapter 2, we addressed an important question regarding the regulation of cytokines in 
the mouse Il10 locus. Because genomic boundaries of the IL-10 gene cluster is not well defined 
in both humans and mice, we cannot exclude the possibility that we are missing distal regulatory 
elements within the hIL10BAC. To investigate this possibility, we took the approach of studying 
the co-expression of the mouse IL-10 and IL-24 mRNAs. We considered the hypothesis that IL-
10 and IL-24 share common regulatory elements that govern their cell-type-specific co-
expression. Our results clearly demonstrate that IL-10 and IL-24 are co-expressed, but are 
regulated by distinct cell-type-specific pathways. The major findings of this work are 
summarized in Table 4.1. We also provided molecular mechanisms for macrophage- and NK-
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specific IL-24 expression, which could be useful to pharmacologically modulate IL-24 
expression independently of IL-10.  




Macrophages NK cells 
IL-24 IL-10 IL-24 IL-10 
Stat6 Yes No Yes No 
Stat4 No No Yes Yes 
Type-I IFNs No Yes Yes No 
 
In the short term, the results from this study can be further expanded to include data from 
a Chromosome Conformation Capture assay (3C). This assay is often used to detect the 
frequency at which genomic loci interact with each other in a given cell at a natural state
(157)
.  3C 
assay has been used with success to investigate chromosomal looping, bringing distal regulatory 
elements as well as associated transcription factors into close proximity to the gene of interest. 
This assay has enabled scientists to study many gene clusters, including the globin locus, TH2 
locus, TH17 locus, and the human IFNG
(11)
. Thus, the absence of long-range chromosomal 
interactions between proximal promoters of Il10 and Il24 in macrophages and NK cells would 
definitely prove that they are not co-regulated in the cell types assayed.  
Altogether, in this dissertation, we designed and generated for the first time a genetically 
humanized mouse to model human genetic variation in non-coding DNA.  This mouse enables 
assessment of inter-individual variability in gene expression and its effect on disease 
susceptibility, which has been difficult to examine until now. Additionally, the hIL10BAC 
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mouse would be useful for testing safety and efficacy of novel drugs targeting IL-10-dependent 
pathways. We also defined the molecular basis governing cell-type-specific expression of 
cytokines, including Il10 and Il24 in the mouse IL-10 locus, which can be useful in defining 
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